<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>607</serviceExecutionTime><Drug id="59098"><DrugName>baricitinib</DrugName><DrugNamesKey><Name id="43093112">Olumiant</Name><Name id="42972754">baricitinib</Name></DrugNamesKey><DrugSynonyms><Name><Value>next-generation Jak inhibitors (inflammation), Incyte</Value></Name><Name><Value>next-generation Jak inhibitors (inflammation/alopecia areata), Eli Lilly/ Incyte</Value></Name><Name><Value>JAK-1/JAK-2 kinase inhibitor (rheumatoid athritis), Eli Lilly/Incyte</Value></Name><Name><Value>baricitinib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>LY-3009104</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>INCB-28050</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>INCB-028050</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Olumiant</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>1187594-09-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17216">Incyte Corp</CompanyOriginator><CompaniesPrimary><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesPrimary><CompaniesSecondary><Company id="17216">Incyte Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="59098" type="Drug"><TargetEntity id="472088" type="siDrug">Baricitinib</TargetEntity></SourceEntity><SourceEntity id="17216" type="Company"><TargetEntity id="4295906783" type="organizationId">Incyte Corp</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="100" type="ciIndication"><TargetEntity id="10061835" type="MEDDRA"></TargetEntity><TargetEntity id="D003928" type="MeSH"></TargetEntity><TargetEntity id="-271673667" type="omicsDisease"></TargetEntity><TargetEntity id="342" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1102" type="ciIndication"><TargetEntity id="L20" type="ICD10"></TargetEntity><TargetEntity id="691" type="ICD9"></TargetEntity><TargetEntity id="10012438" type="MEDDRA"></TargetEntity><TargetEntity id="D003876" type="MeSH"></TargetEntity><TargetEntity id="-1439185598" type="omicsDisease"></TargetEntity><TargetEntity id="456" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1781" type="ciIndication"><TargetEntity id="10037162" type="MEDDRA"></TargetEntity><TargetEntity id="D015535" type="MeSH"></TargetEntity><TargetEntity id="-689721545" type="omicsDisease"></TargetEntity><TargetEntity id="724" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1995" type="ciIndication"><TargetEntity id="K74.3" type="ICD10"></TargetEntity><TargetEntity id="10004661" type="MEDDRA"></TargetEntity><TargetEntity id="186" type="ORPHANET"></TargetEntity><TargetEntity id="422" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2564" type="ciIndication"><TargetEntity id="L63" type="ICD10"></TargetEntity><TargetEntity id="704.01" type="ICD9"></TargetEntity><TargetEntity id="10001761" type="MEDDRA"></TargetEntity><TargetEntity id="D000506" type="MeSH"></TargetEntity><TargetEntity id="-1318275308" type="omicsDisease"></TargetEntity><TargetEntity id="470" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2921" type="ciIndication"><TargetEntity id="D025241" type="MeSH"></TargetEntity><TargetEntity id="-172791506" type="omicsDisease"></TargetEntity><TargetEntity id="753" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3003" type="ciIndication"><TargetEntity id="M08.0" type="ICD10"></TargetEntity><TargetEntity id="D001171" type="MeSH"></TargetEntity><TargetEntity id="-1334562803" type="omicsDisease"></TargetEntity><TargetEntity id="750" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="318" type="ciIndication"><TargetEntity id="M32" type="ICD10"></TargetEntity><TargetEntity id="10042945" type="MEDDRA"></TargetEntity><TargetEntity id="D008180" type="MeSH"></TargetEntity><TargetEntity id="-1461472531" type="omicsDisease"></TargetEntity><TargetEntity id="731" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3564" type="Action"><TargetEntity id="1505" type="Mechanism">Jak2 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3562" type="Action"><TargetEntity id="1506" type="Mechanism">Jak1 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01184" type="ciTarget"><TargetEntity id="137155796837163" type="siTarget">Tyrosine-protein kinase JAK1</TargetEntity><TargetEntity id="431" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01185" type="ciTarget"><TargetEntity id="189436773537173" type="siTarget">Tyrosine-protein kinase JAK2</TargetEntity><TargetEntity id="432" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Rheumatoid arthritis - EU - Apr-2017</FirstLaunched><FirstLaunched>Rheumatoid arthritis - UK - Apr-2017</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1102">Atopic dermatitis</Indication><Indication id="1781">Psoriatic arthritis</Indication><Indication id="1995">Primary biliary cholangitis</Indication><Indication id="2564">Alopecia areata</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="2921">Spondylarthritis</Indication><Indication id="3003">Juvenile rheumatoid arthritis</Indication><Indication id="318">Systemic lupus erythematosus</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="100">Diabetic nephropathy</Indication><Indication id="188">Inflammatory disease</Indication><Indication id="281">Psoriasis</Indication></IndicationsSecondary><ActionsPrimary><Action id="3562">Jak1 tyrosine kinase inhibitor</Action><Action id="3564">Jak2 tyrosine kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="15184">Systemic antipsoriatic product</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="751">Film coating</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="805">Daily dosing</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="595">Tablet formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-07-03T02:54:41.000Z</LastModificationDate><ChangeDateLast>2019-07-03T00:00:00.000Z</ChangeDateLast><AddedDate>2008-01-09T12:24:03.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17810" linkType="Company"&gt;Eli Lilly&lt;/ulink&gt; and   &lt;ulink linkID="17216" linkType="Company"&gt;Incyte&lt;/ulink&gt;  have developed and Lilly launched a next-generation small-molecule JAK-1 and JAK2 kinase inhibitor, baricitinib (Olumiant; LY-3009104; INCB-028050; formerly INCB-28050)  [&lt;ulink linkID="865996" linkType="Reference"&gt;865996&lt;/ulink&gt;], [&lt;ulink linkID="1065190" linkType="Reference"&gt;1065190&lt;/ulink&gt;].  The product is indicated in the EU as a monotherapy or in combination with methotrexate, for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adults who have responded inadequately to, or who are intolerant to, one or more disease modifying antirheumatic drugs (DMARDs) [&lt;ulink linkID="1921426" linkType="Reference"&gt;1921426&lt;/ulink&gt;]. In Japan, baricitinib is indicated for the treatment of RA (including the prevention of structural injury of joints) in patients with inadequate response to standard of care therapies [&lt;ulink linkID="1942601" linkType="Reference"&gt;1942601&lt;/ulink&gt;], [&lt;ulink linkID="1942703" linkType="Reference"&gt;1942703&lt;/ulink&gt;].   In the US, the product is indicated as a monotherapy or in combination with methotrexate or other non-biologic DMARDs, for the treatment of adults with moderately to severely active RA who have had an inadequate response to one or more TNF antagonist therapies [&lt;ulink linkID="2040865" linkType="Reference"&gt;2040865&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2017, the EMA approved the drug for  RA [&lt;ulink linkID="1899930" linkType="Reference"&gt;1899930&lt;/ulink&gt;]. In April 2017, the drug was launched in the UK [&lt;ulink linkID="1918432" linkType="Reference"&gt;1918432&lt;/ulink&gt;], and Germany [&lt;ulink linkID="1921007" linkType="Reference"&gt;1921007&lt;/ulink&gt;]; in July 2017, European launches were ongoing [&lt;ulink linkID="1948273" linkType="Reference"&gt;1948273&lt;/ulink&gt;]. In September 2017, baricitinib  was launched in Japan for  RA  [&lt;ulink linkID="1962811" linkType="Reference"&gt;1962811&lt;/ulink&gt;]. In 2Q18, the drug was launched in the US for patients with moderately to severely active RA who have had an inadequate response to one or more TNF inhibitor therapies [&lt;ulink linkID="2040566" linkType="Reference"&gt;2040566&lt;/ulink&gt;], [&lt;ulink linkID="2058547" linkType="Reference"&gt;2058547&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development in other indications is ongoing. In August 2018, two phase III trials (BRAVE I and BRAVE II) were initiated in patients with systemic lupus erythematosus (SLE) [&lt;ulink linkID="2104302" linkType="Reference"&gt;2104302&lt;/ulink&gt;], [&lt;ulink linkID="2104303" linkType="Reference"&gt;2104303&lt;/ulink&gt;]; in February 2019, phase III development in SLE was ongoing in US, EU and Japan [&lt;ulink linkID="2121188" linkType="Reference"&gt;2121188&lt;/ulink&gt;].  In November 2017,    two   phase III monotherapy trials (BREEZE-AD1 and BREEZE-AD2) were initiated in atopic dermatitis (AD)  [&lt;ulink linkID="2033898" linkType="Reference"&gt;2033898&lt;/ulink&gt;],   [&lt;ulink linkID="2033900" linkType="Reference"&gt;2033900&lt;/ulink&gt;]; in February and March 2018, two further phase III trials (BREEZE-AD5 and long-term trial BREEZE-AD3, respectively) commenced in that setting [&lt;ulink linkID="2033901" linkType="Reference"&gt;2033901&lt;/ulink&gt;], [&lt;ulink linkID="2033894" linkType="Reference"&gt;2033894&lt;/ulink&gt;]; in February 2019, positive results from the BREEZE-AD1 and BREEZE-AD2 studies were reported; at that time, the data were planned to form part of the program intended to support global registrations [&lt;ulink linkID="2116318" linkType="Reference"&gt;2116318&lt;/ulink&gt;]. By February 2017, development of the drug in axial spondyloarthritis was planned [&lt;ulink linkID="1900914" linkType="Reference"&gt;1900914&lt;/ulink&gt;].  In February 2018, a phase III program in psoriatic arthritis (PsA) was expected in 2018 [&lt;ulink linkID="2005757" linkType="Reference"&gt;2005757&lt;/ulink&gt;]; in February 2019, the phase III program in patients with PsA was still planned [&lt;ulink linkID="2120023" linkType="Reference"&gt;2120023&lt;/ulink&gt;]. In September 2018, a phase II/III trial (BRAVE-AA1) in patients with severe alopecia areata was     initiated [&lt;ulink linkID="2050597" linkType="Reference"&gt;2050597&lt;/ulink&gt;]. In December 2018, a phase III trial in juvenile idiopathic arthritis (JIA) was initiated [&lt;ulink linkID="2128708" linkType="Reference"&gt;2128708&lt;/ulink&gt;]. In November 2018, a phase II trial was planned in primary biliary cholangitis [&lt;ulink linkID="2096972" linkType="Reference"&gt;2096972&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Baricitinib was also previously in development for diabetic nephropathy and psoriasis. In December 2011, a phase IIb trial in moderate-to-severe psoriasis began  [&lt;ulink linkID="1249789" linkType="Reference"&gt;1249789&lt;/ulink&gt;], with positive results reported in March 2014  [&lt;ulink linkID="1537089" linkType="Reference"&gt;1537089&lt;/ulink&gt;]. In August 2012, a phase II study for   diabetic kidney disease  began [&lt;ulink linkID="1326195" linkType="Reference"&gt;1326195&lt;/ulink&gt;]; in June 2015, clinical data were presented [&lt;ulink linkID="1668069" linkType="Reference"&gt;1668069&lt;/ulink&gt;]. In April 2016, phase II development for psoriasis and diabetic nephropathy was ongoing [&lt;ulink linkID="1756099" linkType="Reference"&gt;1756099&lt;/ulink&gt;]; however, by July 2016 development for both indications had been discontinued  [&lt;ulink linkID="1784057" linkType="Reference"&gt;1784057&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;A compound patent was set to expire in the US in 2030 and in major European countries, and Japan,  in 2029, not including any possible patent extensions [&lt;ulink linkID="1736462" linkType="Reference"&gt;1736462&lt;/ulink&gt;], [&lt;ulink linkID="1902319" linkType="Reference"&gt;1902319&lt;/ulink&gt;]. In February 2018, Incyte listed  the US, EU and Japan patent states as being 'granted and pending', being  2029 the year occurring the earliest anticipated expirations (subject to potential extensions and payment of maintenance fees) in these regions [&lt;ulink linkID="2005757" linkType="Reference"&gt;2005757&lt;/ulink&gt;]; in February 2019, this was still the case [&lt;ulink linkID="2120023" linkType="Reference"&gt;2120023&lt;/ulink&gt;]. In February 2019, Eli Lilly noted that the Japanese compound patent is slated to expire in 2033 [&lt;ulink linkID="2121188" linkType="Reference"&gt;2121188&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In February 2019, it was planned that data from the BREEZE-AD1 and BREEZE-AD2 studies, which were reported at that time, would form part of the program intended to support global registrations in AD [&lt;ulink linkID="2116318" linkType="Reference"&gt;2116318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2016, an NDA was submitted to the FDA for the treatment of moderate-to-severe RA [&lt;ulink linkID="1728032" linkType="Reference"&gt;1728032&lt;/ulink&gt;].In January 2017, the FDA extended the review period for the NDA by 3 months, to review additional data analyses filed by the company at the FDA's request  [&lt;ulink linkID="1892460" linkType="Reference"&gt;1892460&lt;/ulink&gt;]; in April 2017, the FDA issued a CRL stating that the agency was  unable to approve the application in its current form and indicating that additional clinical data were required to determine dose and further characterize safety concerns [&lt;ulink linkID="1918117" linkType="Reference"&gt;1918117&lt;/ulink&gt;]. In July 2017, Incyte and Lilly reported that the resubmission of the NDA would be delayed beyond 2017, by a minimum of 18 months. At that time, the companies would evaluate the options for resubmission, including the potential for an additional clinical study, as requested by the FDA [&lt;ulink linkID="1947792" linkType="Reference"&gt;1947792&lt;/ulink&gt;]. However, in August 2017, following discussions with the FDA, the NDA was to be resubmitted before the end of January 2018, and include new safety and efficacy data [&lt;ulink linkID="1957580" linkType="Reference"&gt;1957580&lt;/ulink&gt;]; by December 2017,  the NDA had been resubmitted [&lt;ulink linkID="1992220" linkType="Reference"&gt;1992220&lt;/ulink&gt;]; by February 2018, the FDA had classified the application a Class II resubmission with a new 6-month review cycle [&lt;ulink linkID="2005757" linkType="Reference"&gt;2005757&lt;/ulink&gt;]. In April 2018, the FDA's advisory committee voted against  approval of the 4 mg dose, agreeing that both doses were effective but with panelists divided over the safety of the drug. However the committee voted in favor of approving a lower, 2 mg dose for the treatment of  RA [&lt;ulink linkID="2026816" linkType="Reference"&gt;2026816&lt;/ulink&gt;], [&lt;ulink linkID="2026603" linkType="Reference"&gt;2026603&lt;/ulink&gt;]. In June 2018, the FDA approved the 2 mg dose for the treatment of adults with moderately to severely active RA who have had an inadequate response to one or more TNF inhibitor therapies. The approval was based on the phase III clinical trial program, including the RA-BEACON study. At that time, launch was expected by the end of 2Q18 [&lt;ulink linkID="2040566" linkType="Reference"&gt;2040566&lt;/ulink&gt;]. The drug was launched in the US in 2Q 2018 [&lt;ulink linkID="2058547" linkType="Reference"&gt;2058547&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, the FDA granted Orphan designation for pediatric SLE [&lt;ulink linkID="1981412" linkType="Reference"&gt;1981412&lt;/ulink&gt;]. In December 2018, the FDA granted Fast Track designation for SLE [&lt;ulink linkID="2103847" linkType="Reference"&gt;2103847&lt;/ulink&gt;], [&lt;ulink linkID="2104389" linkType="Reference"&gt;2104389&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By January 2016, the drug had  been filed for EU approval for  moderate-to-severely active RA [&lt;ulink linkID="1730341" linkType="Reference"&gt;1730341&lt;/ulink&gt;]. By January 2017, the EMA's CHMP had granted a positive opinion regarding the MAA [&lt;ulink linkID="1896876" linkType="Reference"&gt;1896876&lt;/ulink&gt;]. In February 2017, the EMA approved baricitinib (4 and  2 mg tablets) for the treatment of moderate-to-severe active RA in adults who have responded inadequately to, or who are intolerant to, one or more DMARDs  [&lt;ulink linkID="1899930" linkType="Reference"&gt;1899930&lt;/ulink&gt;]. In April 2017, the drug was launched in the UK [&lt;ulink linkID="1918432" linkType="Reference"&gt;1918432&lt;/ulink&gt;]. Later that month,  the product had been launched in further  European countries, including Germany [&lt;ulink linkID="1921007" linkType="Reference"&gt;1921007&lt;/ulink&gt;]. In June 2017, baricitinib was approved in Switzerland [&lt;ulink linkID="1942703" linkType="Reference"&gt;1942703&lt;/ulink&gt;]. In July 2017, European launches were ongoing [&lt;ulink linkID="1948273" linkType="Reference"&gt;1948273&lt;/ulink&gt;]. By March 2019, there had been additional launches in Europe [&lt;ulink linkID="2146680" linkType="Reference"&gt;2146680&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In 1Q16, a Japanese filing for RA was submitted [&lt;ulink linkID="1770977" linkType="Reference"&gt;1770977&lt;/ulink&gt;]; in May 2017, the MHLW's second Committee on New Drugs, PAFSC recommended approval  of baricitinib for moderate-to-severe RA [&lt;ulink linkID="1937324" linkType="Reference"&gt;1937324&lt;/ulink&gt;]. In July 2017, baricitinib was approved in Japan for the treatment of RA, including the prevention of structural injury of joints, in patients with inadequate response to standard of care therapies based on data from four phase III studies [&lt;ulink linkID="1942601" linkType="Reference"&gt;1942601&lt;/ulink&gt;], [&lt;ulink linkID="1942703" linkType="Reference"&gt;1942703&lt;/ulink&gt;]; in September 2017, launch occurred in Japan for that indication [&lt;ulink linkID="1962811" linkType="Reference"&gt;1962811&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In February 2017, Lilly was developing baricitinib as a class 1 chemical drug in China [&lt;ulink linkID="1897853" linkType="Reference"&gt;1897853&lt;/ulink&gt;]. In March 2018, a filing for approval was submitted in China as a class 5.1 imported drug; in October 2018, the application was granted Priority Review [&lt;ulink linkID="2085262" linkType="Reference"&gt;2085262&lt;/ulink&gt;]. In July 2019, the drug was approved in China for the treatment of moderate-to-severe active RA in adults [&lt;ulink linkID="2169462" linkType="Reference"&gt;2169462&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In August 2018, Health Canada issued a Notice of Compliance for baricitinib (Olumiant) [&lt;ulink linkID="2071617" linkType="Reference"&gt;2071617&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;In June 2017, baricitinib was approved in Kuwait, presumably for RA [&lt;ulink linkID="1942703" linkType="Reference"&gt;1942703&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In November 2017, Eli Lilly was approved to launch the product as Olumiant film-coated tablets in Taiwan, presumably for RA [&lt;ulink linkID="1994366" linkType="Reference"&gt;1994366&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, the agent was approved in Korea [&lt;ulink linkID="1999945" linkType="Reference"&gt;1999945&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2018, baricitinib (Olumiant) was registered in Australia for treatment of moderate to severe active RA in adult patients who have responded inadequately, or who are intolerant, to one or more DMARDs [&lt;ulink linkID="2008046" linkType="Reference"&gt;2008046&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;The US label carries a black box warning highlighting the increased risk of serious infections, malignancy and thrombosis [&lt;ulink linkID="2040865" linkType="Reference"&gt;2040865&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In October 2018, clinical data from two phase III studies which evaluated the percentage of rheumatoid arthritis patients, originally randomized to baricitinib 2 or 4 mg in the RA-BUILD study, and rescued in the study and/or in RA-BEYOND were presented at the 82nd ACR Annual Meeting in Chicago, IL. A total of 15 and 6 patients were rescued in RA-BUILD study at week-16 and 20, respectively, whereas 97 patients were rescued in RA-BEYOND study at any time or after 3 months in RA-BEYOND. A total of 36% of patients on baricitinib 4-mg ‘rescued' in RA-BUILD or RA-BEYOND compared with 52% in patients who were originally assigned to baricitinib 2 mg. Improvement in CDAI, pain, HAQ-DI and SJC-28 outcomes increased and stabilized over time following rescue from baricitinib 2 to 4 mg. Clinically meaningful response rates in achieving low disease activity was found to be increased over time with 33.3% of RA-BUILD patients achieving this level of response at week-128 after rescue and 57.8% of RA-BEYOND patients achieving this level of response at week-120 after rescue  [&lt;ulink linkID="2084399" linkType="Reference"&gt;2084399&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2018, data  from a post-hoc analysis from three phases III studies (RA-BEAM, RA-BUILD and RA-BEACON) to evaluate the hepatic safety of baricitinib in a subset of RA patients who also received isoniazid for the treatment of tuberculosis were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. Small increases in ALT/AST levels were reported in patients who received isonizid treatment versus those that did not; however, increases were consistent across all treatment groups: ALT  increases of &amp;gt; 1-fold the upper limit of normal (ULN) were reported in  40, 33.3, 35.6 and 21.9% of patients who received 4 and 2 mg baricitinib, placebo and adalimumab plus isoniazid, compared with 31.2, 21.8, 21.9 and 30% in those patients who did not receive isoniazid. AST increases were reported in 35, 37, 27.1 and 37.9 versus 25, 17, 15.9, and 22.1% of patients. Few patients showed increases of 3-, 5- or 10-fold the ULN for either parameter [&lt;ulink linkID="2045193" linkType="Reference"&gt;2045193&lt;/ulink&gt;], [&lt;ulink linkID="2045873" linkType="Reference"&gt;2045873&lt;/ulink&gt;]. In June 2018, further clinical data were presented at the Annual European Congress of Rheumatology. In baricitinib (2 versus 4 mg), the proportion of patients achieved American college of Rheumatology (ACR) 20, 50 and 70 was at week 12 and 24 was 44.8 versus 46.3 and 63.1 versus 64.1, 20.1 versus 28.2 and 23.0 versus 29.4, and 12.6 versus 11.3 and 13.2 versus 16.9%, respectively, in RA-BEACON; 63.1 versus 64.1 and 58.2 versus 71.1, 29.5 versus 35.9 and 38.5 versus 49.2, and 15.6 versus 17.2 and 25.4 versus 25%, respectively, in RA-BUILD. In baricitinib 4 mg versus adalimumab groups in RA-BEAM study, the proportion of patients achieved ACR 20 at week 12, 24 and 52 was 68.9 versus 59.9 73.4 versus 67.8 and 70.1 versus 61.0%; ACR 50 was 43.9 versus 31.6, 50.8 versus 49.2 and 57.4 versus 49.2%; ACR 70 was 16.4 versus 9.0, 30.3 versus 19.2, and 40.6 versus 28.8%, respectively. Clinically significant differences in total treatment-emergent adverse events, serious adverse events or adverse events led to study drug discontinuation were not observed between the 2+DMARD-IR and overall study populations [&lt;ulink linkID="2045072" linkType="Reference"&gt;2045072&lt;/ulink&gt;]. In October 2018, further clinical data were presented at the 82nd ACR Annual Meeting in Chicago, IL. In baricitinib-treated patients, median C-reactive protein (CRP) values observed were 6.2 and 3.0 mg/l for the infection and infection-free periods (p &amp;lt; 0.001) and the maximum values were 99.2 and 25.4 mg/l, respectively. In placebo-treated patients, median CRP values were 10.1 and 13.7 mg/l for the infection and infection-free periods (p = 0.896) and the maximum values were 110.8 and 71.4 mg/l, respectively. In placebo- and baricitinib-treated patients, bacterial infections observed were urinary tract infection, cystitis, cellulitis, acute tonsillitis, bronchitis bacterial, ear infection, folliculitis, gingivitis, pharyngitis bacterial, Staphylococcal infection, vaginitis bacterial and wound infection staphylococcal [&lt;ulink linkID="2084314" linkType="Reference"&gt;2084314&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, updated integrated data were presented from eight completed studies and one ongoing long-term extension (LTE) study (14V-MC-JADB, NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT01721044,NCT01721057, NCT01711359, and NCT01885078) which evaluated the safety of baricitinib treatment up to 5.5 years in patients with rheumatoid arthritis, were presented at the 81st ACR Annual Meeting in San Diego, CA. Baricitinib-treated patients were grouped into placebo-baricitinib 4 mg (n = 1070 and 997, respectively), baricitinib 2 mg- baricitinib 4 mg (n = 479 and 479, respectively), and all baricitinib groups (n = 3492). In placebo-baricitinib 4 mg, baricitinib 2 mg- baricitinib 4 mg and all baricitinib groups, the proportion of patients who died were 2 and 3, 1 and 3, and 22, respectively; with serious infection was 17 and 16, 18 and 29, and 194, respectively; and with malignancy excluding nonmelanoma skin cancer was 2 and 2, 3 and 8, and 52, respectively; with lymphoma was 0 each, 0 and 1, and 6, respectively [&lt;ulink linkID="1978284" linkType="Reference"&gt;1978284&lt;/ulink&gt;]. At the same conference, results regarding cardiovascular safety from RA patients included in eight studies were presented.  Incidence rate of major adverse cardiovascular events was 0.5, 0.5, 0.8, 0.2, 0.4, 0, 0.5, 0, 1.1, 0.7 and 0 per 100 patient-years (PY) in all baricitinib RA patients, placebo and baricitinib 4 mg in six-study placebo-controlled 0 to 24 weeks, baricitinib 2 mg and baricitinib 4 mg in dose comparison extended 2 mg versus 4 mg, placebo, baricitinib 4 mg, adalimumab in active comparator RA-BEAM 0 to 24 weeks, methotrexate, baricitinib 4 mg monotherapy and baricitinib 4 mg monotherapy and baricitinib 4 mg + methotrexate, respectively. Signals suggestive of congestive heart failure were not observed [&lt;ulink linkID="1978371" linkType="Reference"&gt;1978371&lt;/ulink&gt;]. At the same conference, additional results were presented. Overall, ten cases of tuberculosis were reported (incidence rate (IR) = 0.15/100 PY), which occurred in tuberculosis-endemic regions and six events were related to extra-pulmonary involvement. Risk of treatment-emergent HZ was high with baricitinib compared to placebo in the placebo-baricitinib 4 mg set (placebo IR = 1.0/100 PY, baricitinib IR = 4.3/100 PY). Fungal events of candiadiasis involving the lung (n = 1), esophagus (n = 6) and soft tissue (n = 1), Pneumocystis jirovecii pneumonia (n = 3, all in Japan) and single cases of histoplasmosis, paracoccidioidomycosis and cryptococcal lung infections, and aspergillosis skin infection were seen [&lt;ulink linkID="1978420" linkType="Reference"&gt;1978420&lt;/ulink&gt;]. In October 2018, further data were presented at the 82nd ACR Annual Meeting in Chicago, IL. The frequency of arterial thrombotic events and major adverse cardiovascular events and its incidence rate were low, comparable across treatments and analysis sets, and did not increase with prolonged exposure. Deep vein thrombosis and/or pulmonary embolism (DVT/PE) events were reported with baricitinib 4 mg but not placebo during the 24-week placebo-controlled period. The imbalance was not replicated during 24 weeks following switch to baricitinib 4 mg from placebo (n = 928, 1 event) or active comparator (n = 451, 0 events). IRs of DVT/PE events were comparable between baricitinib 2 and 4 mg doses at longer exposure [&lt;ulink linkID="2084203" linkType="Reference"&gt;2084203&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;In June 2017, clinical data from four phase III studies (RA-BEGAN, RA-BEAM, RA-BUILD, RA-BEACON) and one long term extension (LTE; RA-BEYOND) study which evaluated the efficacy of baricitinib in patients (n =1453) with active RA were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. Patients were randomized to receive baricitinib (2 or 4 mg, qd) for 52 weeks in originating studies and extended up to 96 weeks in LTE study. At week 52, the proportion of patients achieving SDAI &amp;amp;lt;/=11 was 74.2 and 72.2%; HAQ-DI improvement &amp;gt;/=0.22 was 83.9 and 85.6%; DAS28-hsCRP &amp;amp;lt;/= 3.2 was 70.2 and 70.3% and DAS28-ESR &amp;amp;lt;/= 3.2 was 44.4 and 49.5% at baricitinib 4 mg dose in RA-BEGAN and RA-BEAM studies, respectively. In RA-BEACON study, at week 24, the proportion of patients achieving SDAI &amp;amp;lt;/=11 was 34.2 and 45.2%; HAQ-DI improvement &amp;gt;/=0.22 was 75.2 and 74.2%; DAS28-hsCRP &amp;amp;lt;/= 3.2 was 30.8 and 48.4% and DAS28-ESR &amp;amp;lt;/= 3.2 was 17.9 and 25 at baricitinib 2 and 4 mg doses, respectively. Patients who participated in the LTE study maintained the level of efficacy observed with baricitinib treatment in the originating phase III studies [&lt;ulink linkID="1935713" linkType="Reference"&gt;1935713&lt;/ulink&gt;]. In November 2017, further clinical data were presented at the 81st ACR Annual Meeting in San Diego, CA. At week 12 and 24 post rescue, 70.8 versus 74.5 and 56 versus 66.7% of patients achieved baseline status post-rescue (CDAI remission or low disease activity (LDA)); 97.1 versus 80.9 and 60 versus 72.9% of patients achieved CDAI LDA post-rescue in continued baricitinib versus step down baricitinib groups, respectively. In continued baricitinib 4 mg versus step down baricitinib 2 mg groups, the step down emergent adverse events (AEs; 66.7 versus 59.1%), infection (30.6 versus 24.9%), serious AE (7.5 versus 6.3%), serious infection  (2 versus 1.7%) and AE led to discontinuation (2.7 versus 3.4%), respectively were reported. In both groups, most patients maintained the state of LDA or remission over the 48-week [&lt;ulink linkID="1978332" linkType="Reference"&gt;1978332&lt;/ulink&gt;]. In June 2018, further post-hoc data were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. In 32 baricitinib-treated patients with baseline serology suggestive of prior HBV infection was later tested HBVDNA+ and eight patients were quantifiable. None of the patients developed clinical evidence of hepatitis and in majority of patients (five out of eight) antiviral therapy was not used [&lt;ulink linkID="2045174" linkType="Reference"&gt;2045174&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, data from four phase III studies (RA-BEGIN, RA-BEAM, RA-BUILD and RA-BEACON), which evaluated the temporary interruptions of baricitinib in patients with rheumatoid arthritis, were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. Across treatment groups, interruptions occurred in 8.5 to 18.1% of patients through 24 weeks, and in 22.3 of patients through 52 weeks. Baricitinib interruption led to modest increases in selected rheumatoid arthritis symptoms with the exception of duration of morning stiffness (baricitinib) and the worst tiredness (placebo). After resumption of baricitinib, the increased symptoms returned to pre-interruption levels. Based on ACR20, ACR50, DAS28-hsCRP &amp;lt;/= 3.2, patients who experienced interruptions had similar overall treatment responses compared to patients who did not experience interruption of the study drug [&lt;ulink linkID="1935803" linkType="Reference"&gt;1935803&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, Post hoc analysis data from two phase III studies (RA-BUILD and RA-BEAM) which evaluated the efficacy of baricitinib in patients with rheumatoid arthritis were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. Patients received baricitinib (2 or 4 mg) or placebo. In patients with CDAI &amp;lt;/= 35 to 36 at baseline achieved sustained low disease activity more frequently and more rapidly than patients in the higher disease category at baseline. In patients with higher disease activity at baseline, a more robust response was observed with baricitinib 4 mg treatment [&lt;ulink linkID="1935623" linkType="Reference"&gt;1935623&lt;/ulink&gt;]. Further data based on the concomitant use of conventional synthetic DMARDs (csDMARDs) were presented at the same conference. Regardless of the number and the type of concomitant csDMARDs or concomitant use of corticosteroids, baricitinib demonstrated clinical safety and efficacy in a wide range of patients [&lt;ulink linkID="1935784" linkType="Reference"&gt;1935784&lt;/ulink&gt;]. Further results from a pooled post hoc analysis that examined the effect of smoking on baricitinib efficacy were presented at the same conference. Out of 1429 patients who received placebo or 4 mg baricitinib, 290 patients were smokers. Smoking status at baseline had no impact on the clinical results observed with baricitinib treatment for 12 and 24 weeks. Although the magnitude of difference was small, smokers in placebo group had numerically less likelihood of attaining most clinical outcomes compared to nonsmokers who received placebo. Among non-smokers, treatment effect of baricitinib on the change in mTSS was more profound (interaction p = 0.07) [&lt;ulink linkID="1935596" linkType="Reference"&gt;1935596&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In June 2017, post-hoc pooled analysis data from five randomized, double-blind, placebo-controlled, dose-ranging, parallel group, phase II and III studies (&lt;ulink linkID="82262" linkType="Protocol"&gt;NCT01469013&lt;/ulink&gt;, NCT00902486, NCT01185353, NCT01710358, and NCT01721057) which evaluated the safety and efficacy of baricitinib in patients with rheumatoid arthritis were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. Patients (n = 1684) received baricitinib (4 mg) and placebo. The proportion of patients who achieved ACR20, ACR50, DAS28-hsCRP of &amp;lt;/= 3.2 and the change from HAQ-DI score was greater in baricitinib 4 mg group when compared with placebo for each comorbidity subgroups of patients with and without depression, with and without osteoporosis, with and without hepatic disorders, with and without cardiovascular disorders. Nasopharyngitis and upper respiratory tract infection were the most commonly reported TEAEs in all the subgroups [&lt;ulink linkID="1935716" linkType="Reference"&gt;1935716&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, clinical data from an integrated pooled analysis of completed phase I, II and III studies and an ongoing long-term extension study which evaluated herpes zoster (HZ) in moderate to severe rheumatoid arthritis (RA) patients treated with baricitinib were presented at the 80th ACR Annual Meeting in Washington DC. Treatment with baricitinib was associated with an increased risk of HZ compared with placebo, with an overall IR of 3.3/100 PYO in patients with RA [&lt;ulink linkID="1874085" linkType="Reference"&gt;1874085&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In    November 2016, clinical data from a post hoc analysis of phase III studies which assessed the speed of onset of effect of baricitinib on patient-reported outcomes (PROs) assessed through daily electronic patient diaries in patients with rheumatoid arthritis were presented at the 80th ACR Annual Meeting in Washington DC. Treatment with baricitinib demonstrated rapid improvements in PROs compared with placebo and adalimumab, with significant differences appeared within the initial days of treatment [&lt;ulink linkID="1873979" linkType="Reference"&gt;1873979&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, clinical data from a post hoc analysis of two completed phase III studies which determined whether previous failure of conventional disease-modifying antirheumatic drugs (cDMARDs) altered the response to baricitinib in rheumatoid arthritis patients (n = 1430) were presented at the 80th ACR Annual Meeting in Washington DC. Baricitinib demonstrated clinical efficacy in a wide range of patients with varying exposure to cDMARDs, concomitant use of corticosteroids, serologic status and baseline disease activity [&lt;ulink linkID="1874167" linkType="Reference"&gt;1874167&lt;/ulink&gt;]. Further clinical data were presented at the same conference. Baricitinib 4 mg demonstrated efficacy compared with placebo in US/PR patients and there was no significant safety differences identified [&lt;ulink linkID="1874152" linkType="Reference"&gt;1874152&lt;/ulink&gt;]. Further clinical data were presented at the same conference. Age had not affected baricitinib efficacy in rheumatoid arthritis patients, but there were more AEs in the elderly in both treatment arms [&lt;ulink linkID="1874159" linkType="Reference"&gt;1874159&lt;/ulink&gt;]. Further clinical data were presented at the same conference. Baricitinib was associated with increased LDL-C, HDL-C, and TG levels, with a stable LDL-C/HDL-C ratio [&lt;ulink linkID="1873967" linkType="Reference"&gt;1873967&lt;/ulink&gt;]. Further clinical data were presented at the same conference. There was no clear pattern emerged that showed a consistent effect on baricitinib efficacy. Overall, baseline characteristics were not found to abrogate baricitinib treatment efficacy [&lt;ulink linkID="1873999" linkType="Reference"&gt;1873999&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, clinical data were presented from four phase III studies (RA-BEACON, RA-BUILD, RA-BEAM, and RA-BEGIN), three phase II, one phase Ib, and one ongoing long-term extension study (RA-BEYOND), at the 17th EULAR Annual European Congress of Rheumatology in London, UK. Safety analysis data were reported from a total of 3464 patients. In all baricitinib RA patients, incidence rate (IR) of upper respiratory tract infections, nausea, LDL, adverse event (AE) that lead to temporary interruption, death, AE lead to permanent discontinuation, malignancy (excluded non-melanoma skin cancer), major adverse cardiac event, serious infection and herpes zoster infections were reported in 21.1, 3.4, 44.6, 15.6, 13, 6.1, 0.7, 0.5, 3.2 and 3.4, respectively [&lt;ulink linkID="1767440" linkType="Reference"&gt;1767440&lt;/ulink&gt;]. Further clinical data were presented at the same conference.  Baricitinib received patients reported less absenteeism, presenteeism, and impairment in work productivity of daily activities at the time of primary endpoint and at last follow-up time points, compared with other comparator groups [&lt;ulink linkID="1767433" linkType="Reference"&gt;1767433&lt;/ulink&gt;], [&lt;ulink linkID="1770976" linkType="Reference"&gt;1770976&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. Baricitinib treatment discontinuations due to neutropenia, lymphopenia and lymphocytosis were observed in two, two and one patient, respectively. Within 1 month of baricitinib treatment, mean absolute leukocyte counts were increased and then decreased during weeks 12 to 24. Most neutropenia was low grade; absolute neutrophil count (ANC) of &amp;lt; 1000 cells/mm3 was infrequent. The incidence of neutropenia was not associated with higher risk of overall or serious infections, but lymphopenia associated with a slightly higher rate of overall infections [&lt;ulink linkID="1935765" linkType="Reference"&gt;1935765&lt;/ulink&gt;], [&lt;ulink linkID="1938392" linkType="Reference"&gt;1938392&lt;/ulink&gt;]. Further clinical data were presented at the same conference. From baseline to week 52, a transient reduction in the hemoglobin levels was observed with long term baricitinib treatment. The incidence of treatment emergent abnormality low levels of hemoglobin was comparable between placebo and baricitinib 4 mg, and lower for adalimumab; it was also similar across doses in studies including both baricitinib 2 (30.9%) and 4 mg (35%) [&lt;ulink linkID="1935622" linkType="Reference"&gt;1935622&lt;/ulink&gt;]. At the same conference, further data were presented.  In the all baricitinib rheumatoid arthritis set (n = 3492), serious infection event were reported in 150 patients; the most frequent events were pneumonia, herpes zoster, urinary tract infection, and cellulitis (all &amp;lt; 1%). During 0 to 24 weeks, in the baricitinib 4 mg and placebo groups in the six-study set (n = 997 and 1070, respectively), and between baricitinib 2 mg and 4 mg (n = 479 each) dose groups in the four-study set, the serious infection event rates were similar [&lt;ulink linkID="1935661" linkType="Reference"&gt;1935661&lt;/ulink&gt;], [&lt;ulink linkID="1938392" linkType="Reference"&gt;1938392&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, data were presented from a multicenter, double-blind, double-dummy phase III study performed to evaluate the safety and efficacy of baricitinib, in patients (n = 684) with rheumatoid arthritis were presented at the 79th ACR Annual Meeting in San Francisco, CA. At week 24, a total of 37, 55 and 56% of the patients achieved Health Assessment Questionnaire Disability Index-minimally clinically important difference (MCID) in the placebo, baricitinib 2 and 4 mg groups, respectively [&lt;ulink linkID="1709753" linkType="Reference"&gt;1709753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, lymphocyte subset evaluation was performed in all phase III studies including an ongoing long-term extension study which was planned for future disclosures [&lt;ulink linkID="1709029" linkType="Reference"&gt;1709029&lt;/ulink&gt;] [&lt;ulink linkID="1710926" linkType="Reference"&gt;1710926&lt;/ulink&gt;] [&lt;ulink linkID="1710927" linkType="Reference"&gt;1710927&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, a randomized, double-blind, placebo-controlled, phase III study (&lt;ulink linkID="213468" linkType="Protocol"&gt;NCT02265705&lt;/ulink&gt;; 14875; I4V-CR-JAGS) began in Argentina, Brazil and China to evaluate the efficacy and safety of baricitinib in patients (expected n = 288) with moderate-to-severe RA who have had an inadequate response to methotrexate therapy. The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20%   (ACR20) improvement. At that time, the trial was expected to complete in March 2017 [&lt;ulink linkID="1636030" linkType="Reference"&gt;1636030&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2013, a randomized, parallel-group-assignment, double-blind, multicenter, extension, phase III trial (&lt;ulink linkID="142921" linkType="Protocol"&gt;NCT01885078&lt;/ulink&gt;; 14060, I4V-MC-JADY, 2012-003686-17; RA-BEYOND) was initiated in the US, Argentina, Australia, Europe, India, Israel, South Africa, Korea in patients (expected n = 3073) with RA who had completed a previous baricitinib  study, to assess the  long-term safety of baricitinib for up to 4 additional years [&lt;ulink linkID="1641866" linkType="Reference"&gt;1641866&lt;/ulink&gt;]. In June 2016,  clinical data were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK, showing that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage in patients with RA. At week 48, the least square mean change from baseline in inhibition of progression of joint damage was  0.69, 0.41, and 0.32 (measured by modified total sharp score; mTSS); 0.43, 0.24, and 0.23 (measured by erosion); 0.26, 0.17, and 0.10 (measured by joint space narrowing), in placebo, baricitinib 2 and 4 mg groups, respectively [&lt;ulink linkID="1767180" linkType="Reference"&gt;1767180&lt;/ulink&gt;], [&lt;ulink linkID="1770977" linkType="Reference"&gt;1770977&lt;/ulink&gt;]. In November 2016, further clinical data were presented at the 80th ACR Annual Meeting in Washington DC. Of patients who completed RA-BEAM without rescue, 381 of 394 baricitinib-treated patients and 238 of 241 adalimumab-treated patients entered the LTE. Of these, 185 (continued baricitinib) and 108 adalimumab (switched to baricitinib) patients reached the 24 weeks time point. At week 52, 64 and 76, in baricitinib continued versus switched from adalimumab to baricitinib groups, ACR20 was achieved by 91, 84 and 87 versus 84, 93 and 87% of patients, respectively; ACR50 was achieved by 72, 68 and 76 versus 67, 67 and 65% of patients, respectively; ACR70 was achieved by 45, 46 and 50 versus 42, 48 and 43% of patients, respectively [&lt;ulink linkID="1873914" linkType="Reference"&gt;1873914&lt;/ulink&gt;]. In June 2017, further data of the effects of baricitinib dose reduction were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. At 12, 24 and 48 weeks, dose reduction to 2 mg led to significant increases in disease activity; however, the majority of patients in both groups maintained the state of LDA or remission. For baricitinib 4 and 2 mg, the rescue rates were 7.3 and 17.1%, respectively. Across groups, rates of serious AEs and AEs leading to discontinuation were similar [&lt;ulink linkID="1935729" linkType="Reference"&gt;1935729&lt;/ulink&gt;].  In November 2017, further 12-week vaccine sub study data were presented at the 81st ACR Annual Meeting in San Diego, CA. Administration of pneumococcal and tetanus vaccines during long-term treatment with baricitinib was well-tolerated and resulted in humoral response. At week 5 and 12, 68 and 66%, respectively, of Prevnar 13 treated patients achieved &amp;gt;/= 2 fold increase in concentration for &amp;gt;/= 6/13 serotypes; and 43 and 29%, respectively, of Boostrix treated patients achieved &amp;gt;/= 4 fold increase in concentration. A greater percentage of patients in Boostrix group achieved &amp;gt;/= 2 fold (74 and 56) compared to &amp;gt;/= 4 fold concentration increase at week 5 and 12, respectively [&lt;ulink linkID="1978327" linkType="Reference"&gt;1978327&lt;/ulink&gt;]. In January 2018, the trial was ongoing and expected to complete in March 2024 [&lt;ulink linkID="1641866" linkType="Reference"&gt;1641866&lt;/ulink&gt;]. In June 2018, further clinical data were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. In rescue considering group (RA-BEAM, RA-BUILD and RA-BEACON analysis set), The Clinical Disease Activity Index (CDAI) &amp;lt;/= 10 and &amp;lt;/= 2.8 response was observed in 90 and 40% (week 12), 87 and 43% (week 24) and 80 and 39% (week 48), respectively, in continued baricitinib 4 mg group; 82 and 36% (week 12), 74 and 35% (week 24) and 68 and 32% (week 48), respectively, in step-down baricitinib 2 mg group. In without rescue considering group, the CDAI &amp;lt;/= 10 and &amp;lt;/= 2.8 response was observed in 90 and 40% (week 12), 89 and 44% (week 24) and 86 and 40% (week 48), respectively, in continued baricitinib 4 mg group; 82 and 36% (week 12), 81 and 36% (week 24) and 78 and 36% (week 48), respectively, in step-down baricitinib 2 mg group [&lt;ulink linkID="2045215" linkType="Reference"&gt;2045215&lt;/ulink&gt;].  In October 2018, further data were presented at the 82nd ACR Annual Meeting in Chicago, IL. At week 24 and 48, in baricitinib to baricitinib continued group, SDAI of &amp;lt;/=11  was observed in 77.9 and 78.9% and &amp;lt;/=3.3 was observed in 32.9 and 33.4% of patients, respectively; DAS28-ESR of &amp;lt;/=3.2 was 47.6 and 53.4% and &amp;lt;2.6 was 26.8 and 33.7 %, respectively. At week 24 and 48, in adalimumab to baricitinib switched group (patients completing RA-BEAM on adalimumab who transitioned to baricitinib (week 52) upon entering the LTE), SDAI  of &amp;lt;/=11 was observed in 76.1 and 72.3% and &amp;lt;/=3.3 was observed in 30.7 and 28.6% of patients, respectively; DAS28-ESR of &amp;lt;/=3.2 was 58 and 50.4% and &amp;lt;2.6 was 33.6 and 29.8%, respectively [&lt;ulink linkID="2084400" linkType="Reference"&gt;2084400&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, recruitment began in a randomized, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="96818" linkType="Protocol"&gt;NCT01721044&lt;/ulink&gt;; 14058, I4V-MC-JADW; RA-BEACON) to assess the safety and efficacy of 4 mg of baricitinib administered once a day in moderate-to-severe RA patients (n = 525) who had an inadequate response to a tumor necrosis factor. The trial would be conducted in the US, Canada, India, Argentina, Mexico, Puerto Rico, Japan, Korea,  Australia, Austria, Belgium, Croatia, Denmark,  France, Germany, Greece, Italy, the Netherlands, Poland, Spain, Switzerland, Turkey, the UK, and Israel. At that time, the trial was expected to be completed in November 2014 [&lt;ulink linkID="1386078" linkType="Reference"&gt;1386078&lt;/ulink&gt;]. In December 2014, topline data were reported showing that the 527-patient trial met its primary endpoint of an improved ACR20 response  observed in the baricitinib group compared with placebo after 12 weeks of treatment [&lt;ulink linkID="1619341" linkType="Reference"&gt;1619341&lt;/ulink&gt;]. In June 2015, clinical data were presented at the 16th EULAR Annual European Congress in Rome, Italy. At week 24,  HAQ-DI scores &amp;lt; 0.25 and &amp;gt; 0.5 were achieved by 9.2 and 15.5% of patients, respectively in the baricitinib 2 mg group compared with baricitinib 4 mg group (9.6 and 15.8% of patients, respectively) and placebo (1.1 and 3.4% of patients, respectively) [&lt;ulink linkID="1668392" linkType="Reference"&gt;1668392&lt;/ulink&gt;], [&lt;ulink linkID="1668830" linkType="Reference"&gt;1668830&lt;/ulink&gt;]. At week 24, ACR20, ACR50 and ACR70 response rates were 45, 23 and 13%, respectively in the baricitinib 2 mg group compared with baricitinib 4 mg group (46, 29 and 17% of patients, respectively) and placebo group (27, 13 and 3% of patients, respectively) [&lt;ulink linkID="1669856" linkType="Reference"&gt;1669856&lt;/ulink&gt;], [&lt;ulink linkID="1668830" linkType="Reference"&gt;1668830&lt;/ulink&gt;]. In November 2015, further clinical data in 527 patients were presented at the 79th ACR Annual Meeting in San Francisco, CA. The proportion of patients who achieved DAS28-CRP of &amp;lt;/= 3.2 with prior usage of one TNFi and non-TNFi was 12, 25 and 43% at week 12 and 14, 20 and 49% at week 24; with prior usage of &amp;gt;1 TNFi and non-TNFi was 7, 30 and 24% at week 12 and 10, 24 and 24% at week 24; with prior usage of &amp;lt; 3 biologic DMARDs was 12, 27 and 33 at week 12 and 13, 22 and 36% at week 24; with prior usage of &amp;gt;/= 3 bDMARDs was 2, 18 and 27 at week 12 and 6, 16 and 24% at week 24, in placebo, baricitinib 2 and 4 mg groups, respectively [&lt;ulink linkID="1709028" linkType="Reference"&gt;1709028&lt;/ulink&gt;], [&lt;ulink linkID="1710926" linkType="Reference"&gt;1710926&lt;/ulink&gt;], [&lt;ulink linkID="1710927" linkType="Reference"&gt;1710927&lt;/ulink&gt;]. In November 2015, further data were presented at the 79th ACR Annual Meeting in San Francisco, CA. Baricitinib treatment was associated with inconsistent changes in T cell counts (total, helper, cytotoxic and regulatory cells), elevations in B cell counts (total, memory, naive and transitional cells) and in NK cells followed by reductions [&lt;ulink linkID="1709029" linkType="Reference"&gt;1709029&lt;/ulink&gt;], [&lt;ulink linkID="1710926" linkType="Reference"&gt;1710926&lt;/ulink&gt;], [&lt;ulink linkID="1710927" linkType="Reference"&gt;1710927&lt;/ulink&gt;]. Additional data were also presented at the same conference. After 4 weeks of baricitinib 4 mg treatment, patients with moderate to severe RA who did not experience the pre-defined clinical improvement based on clinical disease activity index  &amp;gt;/= 6 were doubtful to achieve low disease activity or remission at weeks 12 and 24 according to disease activity score 28/ erythrocyte sedimentation rate or simplified disease activity index criteria [&lt;ulink linkID="1709038" linkType="Reference"&gt;1709038&lt;/ulink&gt;], [&lt;ulink linkID="1710926" linkType="Reference"&gt;1710926&lt;/ulink&gt;], [&lt;ulink linkID="1710927" linkType="Reference"&gt;1710927&lt;/ulink&gt;]. In March 2016, further results were published. Significant difference  was not observed for an SDAI score between baricitinib  4 mg and  and the placebo groups  respectively [&lt;ulink linkID="1747627" linkType="Reference"&gt;1747627&lt;/ulink&gt;], [&lt;ulink linkID="1747727" linkType="Reference"&gt;1747727&lt;/ulink&gt;]. In November 2016, further clinical data were reported and published. At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (HAQ-DI &amp;lt;0.5), reductions in fatigue (FACIT-F &amp;gt;/= 3.56), improvements in Patient's Global Assessment of Disease Activity  and pain (p≤0.001) and reductions in duration of morning joint stiffness   [&lt;ulink linkID="1869123" linkType="Reference"&gt;1869123&lt;/ulink&gt;], [&lt;ulink linkID="1869301" linkType="Reference"&gt;1869301&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. Across both the RA-BUILD and RA-BEACON studies, baricitinib 4 mg treated csDMARD-IR and bDMARD-IR patients achieved low disease activity (LDA; p = 0.523 and 0.205, respectively) and sustained LDA (p = 0.58 and 0.373, respectively) more quickly when compared with baricitinib 2 mg treated patients. Baricitinib 4 mg treated patients showed 50% reduction in pain (p = 0.122 and p = 0.172, respectively in bDMARD-IR and cs-DMARD-refractory patients) more quickly and at higher rates compare to baricitinib 2mg in bDMARD-IR patients from RA-BEACON and csDMARD-refractory patients from RA-BUILD [&lt;ulink linkID="1935750" linkType="Reference"&gt;1935750&lt;/ulink&gt;]. At the same conference, further data of the effect of baricitinib on pain reduction were presented. Significantly greater proportion of baricitinib 4 mg-treated patients achieved &amp;gt;/= 30 and &amp;gt;/= 50% improvement in pain compared to placebo as early as week 1. Significant pain improvement of &amp;gt;/= 70% was achieved at week 1 by baricitinib 4 mg-treated patients compared to placebo [&lt;ulink linkID="1935771" linkType="Reference"&gt;1935771&lt;/ulink&gt;].In October 2018, further data were presented at the 82nd ACR Annual Meeting in Chicago, IL. In placebo for 24 weeks, baricitinib 2 and 4 mg for 24 weeks groups, the mean FACIT-F standard score was 28.9, 31.5 and 33.2, respectively; the mean PROMIS Fatigue score from 13-item FACIT-F crosswalk was 58.2, 56.0 and 54.4, respectively; the mean PROMIS Fatigue score from 10-item FACIT-F crosswalk was 59.1, 57.5 and 55.5, respectively; the mean PROMIS Fatigue score from 13-item FACIT-F pattern scoring was 57.1, 55.5 and 54.0, respectively; and the mean PROMIS Fatigue score from 10-item FACIT-F pattern scoring was 56.6, 55.2 and 53.7, respectively [&lt;ulink linkID="2084161" linkType="Reference"&gt;2084161&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In December 2012,  a randomized, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="96907" linkType="Protocol"&gt;NCT01721057&lt;/ulink&gt;; 14059; I4V-MC-JADX; RA-BUILD) was initiated in the US, Argentina, Australia, Europe, Canada, India, Japan, Korea, Mexico, Puerto Rico, Taiwan, and the UK to evaluate the efficacy and safety of baricitinib in patients (n = 678) with moderate-to-severe RA with inadequate response to conventional disease-modifying antirheumatic drugs (DMARDS). The primary endpoint was the proportion of patients achieving an ACR20 improvement. In December 2014, the trial was completed [&lt;ulink linkID="1636023" linkType="Reference"&gt;1636023&lt;/ulink&gt;]. In February 2015, data were reported from 684 patients, demonstrating that the trial met its primary endpoint with an improved ACR20 response rate in baricitinib-treated patients compared with placebo after 12 weeks of treatment [&lt;ulink linkID="1635663" linkType="Reference"&gt;1635663&lt;/ulink&gt;]. In June 2015, clinical data were presented at the 16th EULAR Annual European Congress in Rome, Italy. At week 24, ACR20, ACR50 and ACR70 response rates were 61, 42 and 25%, respectively in the baricitinib 2 mg group compared with baricitinib 4 mg group (65, 44 and 24%, respectively) and placebo (42, 22 and 8%, respectively) [&lt;ulink linkID="1669855" linkType="Reference"&gt;1669855&lt;/ulink&gt;], [&lt;ulink linkID="1668830" linkType="Reference"&gt;1668830&lt;/ulink&gt;]. In November 2015, further data were presented at the 79th ACR Annual Meeting in San Francisco, CA. Baricitinib treatment was associated with inconsistent changes in T cell counts (total, helper, cytotoxic and regulatory cells), elevations in B cell counts (total, memory, naive and transitional cells) and in NK cells followed by reductions [&lt;ulink linkID="1709029" linkType="Reference"&gt;1709029&lt;/ulink&gt;], [&lt;ulink linkID="1710926" linkType="Reference"&gt;1710926&lt;/ulink&gt;], [&lt;ulink linkID="1710927" linkType="Reference"&gt;1710927&lt;/ulink&gt;]. Additional data were presented at the same conference. After 4 weeks of baricitinib 4 mg treatment, patients with moderate to severe RA who did not experience the pre-defined clinical improvement based on clinical disease activity index  &amp;gt;/= 6 were doubtful to achieve low disease activity or remission at weeks 12 and 24 according to disease activity score 28/ erythrocyte sedimentation rate or simplified disease activity index criteria [&lt;ulink linkID="1709038" linkType="Reference"&gt;1709038&lt;/ulink&gt;], [&lt;ulink linkID="1710926" linkType="Reference"&gt;1710926&lt;/ulink&gt;], [&lt;ulink linkID="1710927" linkType="Reference"&gt;1710927&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. At week 24, % of patients with SDAI (&amp;lt;/=11) were 29, 48, and 52; CDAI (&amp;lt;/=10) were 28, 45, and 52, respectively in placebo, baricitinib 2 and 4 mg, treatment groups. Least square mean change from baseline in inhibition of progression of joint damage, at week 24 was 0.57, 0.26, and 0.25 (measured by modified total sharp score (mTSS)); 0.36, 0.18, and 0.17 (by erosion); 0.21, 0.08, and 0.08 (joint space narrowing) [&lt;ulink linkID="1767180" linkType="Reference"&gt;1767180&lt;/ulink&gt;], [&lt;ulink linkID="1770977" linkType="Reference"&gt;1770977&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. In csDMARD-IR patients, progression with initial baricitinib was lower relative to initial placebo. There were significant differences in mTSS and bone erosion observed for baricitinib 4 mg group, but not the 2 mg group, when compared with initial placebo [&lt;ulink linkID="1935603" linkType="Reference"&gt;1935603&lt;/ulink&gt;].  Further clinical data were presented at the same conference. Across both the RA-BUILD and RA-BEACON studies, baricitinib 4 mg treated csDMARD-IR and bDMARD-IR patients achieved low disease activity (LDA; p = 0.523 and 0.205, respectively) and sustained LDA (p = 0.58 and 0.373, respectively) more quickly when compared with baricitinib 2 mg treated patients. Baricitinib 4 mg treated patients showed 50% reduction in pain (p = 0.122 and p = 0.172, respectively in bDMARD-IR and cs-DMARD-refractory patients) more quickly and at higher rates compare to baricitinib 2mg in bDMARD-IR patients from RA-BEACON and csDMARD-refractory patients from RA-BUILD [&lt;ulink linkID="1935750" linkType="Reference"&gt;1935750&lt;/ulink&gt;]. In October 2018, further data on joint-related biomarkers were presented at the 82nd ACR Annual Meeting in Chicago, IL. Baricitinib significantly reduced C1M, C3M, and C4M (MMP-derived fragments of type I, III, and IV collagen, respectively) compared to placebo. Baricitinib had no significant effect on other biomarkers (ProC3, C2M, CTX-1 and osteocalcin) compared to placebo; significant differences were also not observed between baricitinib 2 and 4 mg dose. Compared to patients with increased levels of C1M, C3M, and C4M biomarkers, patients with decreased levels of these biomarkers by weeks 4 and 12 had significantly greater clinical improvement in the Hybrid ACR, CDAI and DAS28-ESR responses at Week 12 [&lt;ulink linkID="2084148" linkType="Reference"&gt;2084148&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, a randomized, double-blind, placebo- and active-controlled, phase III trial (&lt;ulink linkID="95383" linkType="Protocol"&gt;NCT01710358&lt;/ulink&gt;; 13978, I4V-MC-JADV; RA-BEAM; CTR20130899) was initiated in the US, Argentina, Europe, Canada, China,  Japan, Korea, Mexico, Puerto Rico, South Africa, Taiwan and the UK to assess superiority of baricitinib over placebo in moderate-to-severe RA patients who had an inadequate response to methotrexate treatment (expected n = 1280) [&lt;ulink linkID="1387846" linkType="Reference"&gt;1387846&lt;/ulink&gt;]. In October 2015, topline data were reported, which showed that the trial met its primary endpoint.   At 12 weeks, was baricitinib was superior to placebo in ACR20 response. Additionally, baricitinib was superior to &lt;ulink linkID="14163" linkType="Drug"&gt;adalimumab&lt;/ulink&gt; in ACR20 response and improving the DAS28-hsCRP score after 12 weeks. After 24 weeks, baricitinib was superior to placebo in preventing progressive radiographic structural joint damage. The treatment benefits observed at 12 and 24 weeks were maintained over  52 weeks of therapy. At that time, more than 1300 patients were enrolled in the trial [&lt;ulink linkID="1702963" linkType="Reference"&gt;1702963&lt;/ulink&gt;].  In November 2015,  data were presented at the 79th ACR Annual Meeting in San Francisco, CA.  DAS28-C-reactive protein and DAS-ESR activity was reported in 56 versus 48% and 39 versus 36% of the patients in the baricitinib versus adalimumab groups, at week 52. A total of 70.4, 79.1 and 81.1% of the patients showed no progression of mTSS at week 52 in the placebo, baricitinib and adalimumab groups, respectively. At week 24, the LDL/HDL ratio was 2.06, 2.07 and 2.05 in the placebo, baricitinib and adalimumab groups, respectively [&lt;ulink linkID="1710172" linkType="Reference"&gt;1710172&lt;/ulink&gt;],  [&lt;ulink linkID="1710926" linkType="Reference"&gt;1710926&lt;/ulink&gt;], [&lt;ulink linkID="1710927" linkType="Reference"&gt;1710927&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. Baricitinib treatment reported significant improvements in PROs across different domains which included physical function, MJS, fatigue, pain, and quality of life, compared with placebo [&lt;ulink linkID="1767875" linkType="Reference"&gt;1767875&lt;/ulink&gt;], [&lt;ulink linkID="1770976" linkType="Reference"&gt;1770976&lt;/ulink&gt;]. Further clinical data were presented at same conference. At weeks 0 to 12, lymphocyte common terminology criteria for adverse events (CTCAE) of grade 1 (&amp;gt;/=800 to &amp;lt;1100 cells/microl) was reported in 10.1, 7.6 and 6.1; grade 2 (&amp;gt;/=500 to &amp;lt;800 cells/microl) in 5.7, 2.5, and 2.4%;  grade 3 (&amp;gt;/=200 to &amp;lt;500 cells/microl) in 1.0, 0.4, and 0% of patients, respectively in placebo, baricitinib, and adalimumab treatment groups. At week 0 to 24, lymphocyte CTCAE grade 1 was reported in 13.6, 12.2, and 8.8; grade 2 in 6.8, 5.6, and 3.6; grade 3 in 1.8, 0.8, and 0.3% of patients in placebo, baricitinib, and adalimumab treatment groups, respectively [&lt;ulink linkID="1768026" linkType="Reference"&gt;1768026&lt;/ulink&gt;]. Further data were presented at same conference. Lipoprotein change from baseline at week 12, in placebo, baricitinib, and adalimumab group was -22.4, 15.0, and -33.9 (total LDL particles); -0.03, 4.8, and 2.0 (HDL particles); -1.7, 12.0, and 6.1 (VLDL particles), respectively. Baricitinib and adalimumab treatment resulted in significant mean increase from baseline in total cholesterol, triglycerides, LDL and HDL cholesterol, at week 12 and was persisted through week 52 [&lt;ulink linkID="1767406" linkType="Reference"&gt;1767406&lt;/ulink&gt;]. Further data were presented at same conference.  Rapid decrease in disease activity score-28 (DAS-28) was noted in 7, 24, and 2 (at week 12); 10, 32, and 34 (week 24); not evaluable (NE), 31, and 36 (week 52); and further simplified disease activity index (SDAI) was noted in 16, 42, and 36 (at week 12); 20, 51, and 43 (week 24); not evaluable (NE), 57, and 43 (week 52) % of patients in placebo, baricitinib, and adalimumab groups, respectively. LDA by improvement in CDAI &amp;gt;/= 6 at week 4, was observed in 3 and 11 (early responders); 28 and 37 (non responders) % of patients in baricitinib group of RA-BEAM study at week 12 and 24, respectively. [&lt;ulink linkID="1767870" linkType="Reference"&gt;1767870&lt;/ulink&gt;]. In February 2017, similar data were  published. A higher portion of baricitinib recipients achieved ACR50 and ACR70, as early as week 8 and sustained through week 52, compared with adalimumab recipients. The ACR50 and ACR70 rates were statistically significant versus adalimumab at weeks 12, 20, 28, 32 and 40. At week 52, the ACR50 rate was statistically significant [&lt;ulink linkID="1900952" linkType="Reference"&gt;1900952&lt;/ulink&gt;], [&lt;ulink linkID="1900789" linkType="Reference"&gt;1900789&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. In methotrexate-IR patients, the inhibition of progression of joint damage with initial baricitinib 4 mg was lower relative to initial placebo, and similar to initial adalimumab [&lt;ulink linkID="1935603" linkType="Reference"&gt;1935603&lt;/ulink&gt;]. Further clinical data were presented at the same conference. At week 12, a &amp;gt;/= 30% reduction in pain at week 1 was associated with significantly greater (p &amp;lt; 0.001) improvement in regular daily activity, presenteeism, and work productivity than a &amp;lt; 30% pain reduction. Regardless of treatment, absenteeism was improved at week 12 when pain was reduced &amp;gt;/= 30% at week 4.  A &amp;gt;/= 30% reduction in pain with baricitinib 4 mg  at week 12 was found to be associated with statistically significantly greater improvement in all four WPAI-RA scores at week 12 when compared with &amp;lt; 30% reduction pain [&lt;ulink linkID="1935752" linkType="Reference"&gt;1935752&lt;/ulink&gt;], [&lt;ulink linkID="1938392" linkType="Reference"&gt;1938392&lt;/ulink&gt;]. At the same conference, further data comparing the improvement according to Routine Assessment of Patient Index Data (RAPID)3, DAS28-ESR, and CDAI were presented. In all treatment groups, changes according to RAPID3-like, DAS28-ESR and CDAI were similar; according to all indices, baricitinib and adalimumab were superior to placebo, and according to RAPID3-like and CDAI, baricitinib was superior to adalimumab. At week 24, the proportion of patients with low activity/severity/remission ranged from 9.6 to 19.7% in placebo group, 31.6 to 49.9% in baricitinib group, and 33.6 to 47.6% in adalimumab group [&lt;ulink linkID="1935690" linkType="Reference"&gt;1935690&lt;/ulink&gt;]. Further data comparing the PROs in patients who achieved LDA or remission to those with moderate or high disease activity (MDA and HDA) based upon DAS28- ESR were presented at the same conference. At week 24, greater improvements in pain and other PROs (HAQ-DI, SF-36 PCS, SF-36 MCS, and FACIT-T) as well as less remaining/residual pain were observed in patients who achieved LDA and remission compared to patients who achieved MDA and HDA  [&lt;ulink linkID="1935536" linkType="Reference"&gt;1935536&lt;/ulink&gt;]. At the same conference, further data of the effect of baricitinib on pain reduction were presented. Significantly greater proportion of baricitinib 4 mg-treated patients achieved &amp;gt;/= 30 and &amp;gt;/= 50% improvement in pain compared to placebo as early as week 1, and compared to adalimumab as early as week 4. Significant pain improvement of &amp;gt;/= 70% was achieved at week 1 by baricitinib 4 mg-treated patients compared to placebo, and at week 8 compared to adalimumab [&lt;ulink linkID="1935771" linkType="Reference"&gt;1935771&lt;/ulink&gt;]. Further data regarding PROs among patients who achieved LDA or in remission were presented at the same conference. In 24 placebo-, 87 baricitinib- and 57 adalimumab-treated patients in remission, mean change from baseline to week 24 in pain VAS score was -27.3, -46.4 (p &amp;lt; 0.01 versus placebo) and -36.7 and in activity impairment was -20.0, -37.7 and -26.7, respectively. In 46 placebo-, 154 baricitinib- and 110 adalimumab-treated patients with LDA, change in mean pain VAS score from baseline to week 24 was -26.8, -45.9 (p &amp;lt; 0.001 versus adalimumab) and -38.2 and in activity impairment was -23.5, 36.8 and -30.3, respectively [&lt;ulink linkID="1935556" linkType="Reference"&gt;1935556&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. The cumulative incidence for the first transitions to good EULAR response at weeks 12, 24 and 52 was higher in patients who reached moderate EULAR responses at week 4 on baricitinib than those on adalimumab [&lt;ulink linkID="1935594" linkType="Reference"&gt;1935594&lt;/ulink&gt;].  In November 2017, further data were presented at the 81st ACR Annual Meeting in San Diego, CA. At week-12, 78 patients demonstrated &amp;lt;/= 15% reduction in hsCRP, while 298 patients had &amp;gt;/= 70% reduction in hsCRP. An association between a greater decline in hsCRP at week 12 and greater decline in mean neutrophil count at week 8 was observed. Similar proportion of patients achieved LDA (42%) and remission (26%) with decrease in neutrophil count. The proportion of patients who achieved LDA or remission decreased with increasing levels of ANC; the decrease was dose-dependent [&lt;ulink linkID="1978288" linkType="Reference"&gt;1978288&lt;/ulink&gt;]. Further data were presented at the same conference. In placebo, baricitinib and adalimumab groups, the mean percentage change in GlycA levels from baseline to week-12 was 508.9, 517.2 and 513.9 microM, respectively; and to week-24 was 496.9, 404.3 and 416.3 microM, respectively [&lt;ulink linkID="1978202" linkType="Reference"&gt;1978202&lt;/ulink&gt;]. At the same conference, further  post hoc analysis data were presented. In placebo, baricitinib and adalimumab groups, the least square mean change in CDAI improvement from baseline to week 12 was -12.9, -22.0 (p = &amp;lt; 0.001 and 0.01 versus placebo and adalimumab) and -19.5 (p &amp;lt; 0.001 versus placebo), respectively; and to week-24 was -13.6, -24.2 (p &amp;lt; 0.001 and &amp;lt; 0.05) and -22.1 (p &amp;lt; 0.001), respectively. In baricitinib and adalimumab groups, the least square mean change in CDAI improvement from baseline to week 52 was -25.5 (p &amp;lt; 0.01) and -22.6, respectively. At the primary time point (week 12) and at weeks 24 and 52, significantly lower cumulative disease activity was observed in patients treated with baricitinib compared to adalimumab [&lt;ulink linkID="1978246" linkType="Reference"&gt;1978246&lt;/ulink&gt;]. Further post hoc analysis data were presented at the same conference. In methotrexate-inadequate responder patients with moderate to severely active RA, baricitinib treatment demonstrated faster and greater pain improvement through week 24 compared to adalimumab or placebo. Regardless of baseline pain severity, baricitinib treatment exhibited similar rapid median time to reach pain response threshold. Greater baricitinib total effect (indirect effect + direct pain reduction) on pain reduction was observed for baricitinib over placebo compared to adalimumab over placebo. Compared to adalimumab, baricitinib treatment demonstrated greater pain reduction in patients with residual levels of C-reactive protein [&lt;ulink linkID="1978474" linkType="Reference"&gt;1978474&lt;/ulink&gt;]. Further data from patients who failed adalimumab or placebo treatment and were rescued with baricitinib were presented at the same conference. At 4 weeks after rescue in patients who failed placebo or adalimumab, significant improvements in pain, physical function (HAQ-DI, SF-36 PCS), fatigue (FACIT-F) and duration of MJS observed were  sustained through 12 weeks [&lt;ulink linkID="1978336" linkType="Reference"&gt;1978336&lt;/ulink&gt;]. At the same conference, further data were presented. Gene expression profiling revealed significant differences between treatments; notably, baricitinib and adalimumab modulated JAK/STAT or complement pathways, respectively, and the drugs had opposite effects on IFNs [&lt;ulink linkID="1978432" linkType="Reference"&gt;1978432&lt;/ulink&gt;]. In June 2018, further post hoc analyses data were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. At weeks 12 and 24, reductions in pain and fatigue were associated with improved regular daily activities, presenteeism, and work productivity in RA, with larger reductions related to more improvement. When compared with patients with higher levels of pain or fatigue, patients with lower levels of pain and fatigue tended to experience greater improvement in presenteeism, work productivity, and regular daily activities [&lt;ulink linkID="2045197" linkType="Reference"&gt;2045197&lt;/ulink&gt;]. Further data were presented at the same conference. Among patients in remission at week 12, the proportion of patients who    attained limited/no pain was numerically higher in baricitinib (83%) group relative to adalimumab (73%) and placebo (67%) groups; at week 24, these percentages were 81, 82, and 63% for baricitinib, adalimumab, and placebo groups, respectively [&lt;ulink linkID="2045186" linkType="Reference"&gt;2045186&lt;/ulink&gt;]. In October 2018, further data were presented at the  82nd ACR Annual Meeting in Chicago, IL.Overall disease activity was similar if patients had early or delayed start baricitinib; early starters had faster efficacy [&lt;ulink linkID="2084437" linkType="Reference"&gt;2084437&lt;/ulink&gt;], [&lt;ulink linkID="2085484" linkType="Reference"&gt;2085484&lt;/ulink&gt;]. Further clinical data were presented at the same conference. Significant increase in platelet count and reduction in mean platelet volume from baseline  to week 2 was observed with baricitinib; both then returned to baseline and remained stable through week 16 [&lt;ulink linkID="2084451" linkType="Reference"&gt;2084451&lt;/ulink&gt;]. Further data were presented at the same conference. In placebo for 24 weeks, baricitinib 4 mg for 24 and 52 weeks, adalimumab for 24 and 52 weeks groups, the mean FACIT-F standard score was 35.3, 38.5, 38.9, 37.6 and 37.5, respectively; the mean Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue score from 13-item FACIT-F crosswalk was 53.1, 50.2, 50.1, 51.1 and 51.0, respectively; the mean PROMIS Fatigue score from 10-item FACIT-F crosswalk was 53.9, 51.4, 51.1, 52.0 and 51.9, respectively; the mean PROMIS Fatigue score from 13-item FACIT-F pattern scoring was 52.7, 50.3, 49.9, 51.0 and 51.0, respectively; and the mean PROMIS Fatigue score from 10-item FACIT-F pattern scoring was 52.3, 50.1, 49.7, 50.7 and 50.7, respectively [&lt;ulink linkID="2084161" linkType="Reference"&gt;2084161&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2012, a randomized, double-blind, active-controlled, phase III trial (&lt;ulink linkID="95515" linkType="Protocol"&gt;NCT01711359&lt;/ulink&gt;; 14062, I4V-MC-JADZ; RA-BEGIN) to assess non-inferiority of the drug when administered alone compared with methotrexate in moderate-to-severe RA patients who were naive to DMARDS (n = 550). The trial would be conducted in the US, Canada, India, Argentina, Brazil, Mexico, Puerto Rico, Japan, Korea,  Europe, the UK, and South Africa [&lt;ulink linkID="1386085" linkType="Reference"&gt;1386085&lt;/ulink&gt;].  In September 2015, topline data were reported, which showed that trial met its primary endpoint. At 24 weeks, baricitinib was non-inferior to methotrexate in ACR20 response rate, and was superior based on ACR20 response [&lt;ulink linkID="1698637" linkType="Reference"&gt;1698637&lt;/ulink&gt;]. In November 2015, further clinical data were presented at the 79th ACR Annual Meeting in San Francisco, CA. Significant improvement in sign and symptoms, physical function and patient reported outcomes were observed in patients receiving 4 mg baricitinib when compare to methotrexate monotherapy. New safety or tolerability issues were not identified with baricitinib [&lt;ulink linkID="1709026" linkType="Reference"&gt;1709026&lt;/ulink&gt;], [&lt;ulink linkID="1710926" linkType="Reference"&gt;1710926&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. Least-square mean change from baseline at week 24 of physical function, patient's global assessment of disease activity, patient's assessment of RA pain, health state index score, and self-perceived health score at week 24 was -0.74, -1.04, and -1.03;  -31, -41, and -40; -30, -41, and -41; 0.200, 0.288, and 0.288; 15, 24, and 22, respectively; and at week 52, -0.71, -0.99 and -1.06; -29, -40, and -43; -31, -40, and -43; 0.191, 0.272, and 0.273; 14, 25, and 25, respectively with methotreaxate, baricitinib, and combination therapy. Percent activity impairment due to RA after methotreaxate, baricitinib, and combination was 61, 62, and 59 (at baseline); -25, -37, and -33 (at week 24); -29, -35 and -38 (at week 52), respectively [&lt;ulink linkID="1767421" linkType="Reference"&gt;1767421&lt;/ulink&gt;], [&lt;ulink linkID="1770976" linkType="Reference"&gt;1770976&lt;/ulink&gt;]. Further data were presented at same conference. Decrease in DAS-28 was reported by 23, 35, and 39 (week 24); 27, 36, and 43 (week 52); SDAI in 40, 62, and 61 (week 24); 41, 60, and 62 (week 52) % of patients in methotrexate, baricitinib and combination group, respectively.   LDA by improvement in CDAI was noted in 0 and 17 (responders); 27 and 43 (non responders) % of patients at week 12 and 24, in baricitinib group of RA-BEGIN study, respectively [&lt;ulink linkID="1767870" linkType="Reference"&gt;1767870&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. In DMARD-naive patients, the combination of baricitinib + methotrexate significantly inhibited progression of structural joint damage as measured by modified total sharp score (mTSS) and the bone erosion subcomponent when compared with initial methotrexate. Baricitinib monotherapy significantly inhibited the bone erosion subcomponent compared to initial methotrexate [&lt;ulink linkID="1935603" linkType="Reference"&gt;1935603&lt;/ulink&gt;]. Further  clinical data were presented at the same conference. At weeks 0, 4, 12 and 32, a slight decline in absolute lymphocyte count, CD3+, CD8+, B (CD19+), and NK cells was observed at post-baseline visits for methotrexate group; while for baricitinib and baricitinib + methotrexate groups, cell counts increased for all cell types except B-cells at week 4 and 12, and a return towards baseline or slightly below was observed at week 32. In patients treated with methotrexate, baricitinib and baricitinib + methotrexate, overall serious infection rates were 3.8, 3.8, and 2.3%, respectively, and herpes zoster rates were 1.0, 2.5 and 2.3%, respectively, in all patients [&lt;ulink linkID="1935659" linkType="Reference"&gt;1935659&lt;/ulink&gt;], [&lt;ulink linkID="1938392" linkType="Reference"&gt;1938392&lt;/ulink&gt;]. Further post hoc analysis data were presented at the same conference. Compared to patients who did not achieve sustained DAS-hsCRP &amp;lt;/= 3.2 at weeks 16, 20 and 24, patients who achieved the response exhibited lower rates of structural progression. When compared to patients with lower rate of structural progression, patients who achieved sustained DAS-hsCRP &amp;lt;/= 3.2 at weeks 16, 20 and 24 with baricitinib as monotherapy or combination demonstrated lower rates of progression [&lt;ulink linkID="1935679" linkType="Reference"&gt;1935679&lt;/ulink&gt;], [&lt;ulink linkID="1938392" linkType="Reference"&gt;1938392&lt;/ulink&gt;]. In November 2017, further data of the factors associated with risk of radiographic progression after 52 weeks of treatment with baricitinib monotherapy, methotrexate monotherapy, or a combination of these two drugs were presented at the 81st ACR Annual Meeting in San Diego, CA. In methotrexate, baricitinib and baricitinib + methotrexate groups, the proportion of patients with radiographic progression at week-52 was 19.0, 12.0 and 7.4%, respectively. Radiographic progression was more likely seen in females, smokers, patients with higher baseline hsCRP, higher baseline CDAI and lower BMI [&lt;ulink linkID="1978342" linkType="Reference"&gt;1978342&lt;/ulink&gt;]. At the same conference, results regarding pain control attainment were presented. At 24 weeks, a greater proportion of patients in the baricitinib group reported less remaining  pain versus those in the methotrexate group. The time for 50% of patients to attain 50% pain improvement was 12, 4 and 4 weeks for methotrexate, baricitinib and methotrexate + baricitinib, respectively (p &amp;lt; 0.001 for baricitinib and methotrexate + baricitinib versus methotrexate). The time when 50% of patients attained 70% pain improvement was 20 weeks for methotrexate and 8 to 12 weeks for baricitinib and methotrexate + baricitinib (p &amp;lt; 0.001 for baricitinib and methotrexate + baricitinib versus methotrexate). Overall, greater disease activity control was associated with lower levels of remaining pain across all treatment groups [&lt;ulink linkID="1978310" linkType="Reference"&gt;1978310&lt;/ulink&gt;]. In June 2018, further post hoc analysis data were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. Among patients in remission, the proportion of patients attained limited/no pain at week 12 was numerically higher for baricitinib (96%) relative to baricitinib + methotrexate (82%) or methotrexate (64%); limited/no pain at week 24 was reported in 68, 87 and 77% of patients treated with baricitinib, baricitinib + methotrexate, and methotrexate, respectively [&lt;ulink linkID="2045186" linkType="Reference"&gt;2045186&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2012, Incyte was planning a phase III RA trial [&lt;ulink linkID="1284380" linkType="Reference"&gt;1284380&lt;/ulink&gt;]. In October 2012, screening of patients was began [&lt;ulink linkID="1336757" linkType="Reference"&gt;1336757&lt;/ulink&gt;]. In November 2012, a phase III RA program was initiated and at the time, four phase III RA trials were  planned. The trials would assess safety and efficacy of baricitinib (2 and 4 mg) once-daily in methotrexate-naive, biologic-naive or biologic-experienced RA patients. Those completing any of the studies would be eligible for a fifth, long-term extension study [&lt;ulink linkID="1341164" linkType="Reference"&gt;1341164&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2017, updated integrated data were presented from eight completed studies and one ongoing long-term extension (LTE) study (14V-MC-JADB, NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT01721044, NCT01721057, NCT01711359, and NCT01885078) which evaluated the safety of baricitinib treatment up to 5.5 years in patients with rheumatoid arthritis, were presented at the 81st ACR Annual Meeting in San Diego, CA. Baricitinib-treated patients were grouped into placebo-baricitinib 4 mg (n = 1070 and 997, respectively), baricitinib 2 mg- baricitinib 4 mg (n = 479 and 479, respectively), and all baricitinib groups (n = 3492). In placebo-baricitinib 4 mg, baricitinib 2 mg- baricitinib 4 mg and all baricitinib groups, the proportion of patients who died were 2 and 3, 1 and 3, and 22, respectively; with serious infection was 17 and 16, 18 and 29, and 194, respectively; AND with malignancy excluding nonmelanoma skin cancer was 2 and 2, 3 and 8, and 52, respectively; with lymphoma was 0 each, 0 and 1, and 6, respectively [&lt;ulink linkID="1978284" linkType="Reference"&gt;1978284&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By December 2011, phase II trials for RA had been initiated in Japan [&lt;ulink linkID="1256042" linkType="Reference"&gt;1256042&lt;/ulink&gt;]. Data from a 12-week, blinded phase IIb study of baricitinib in Japanese patients (n = 145) with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate were presented in October 2013 at the 77th ACR/ARHP Annual Meeting in San Diego CA. In the 1, 2, 4 and 8 mg and placebo groups, 67, 83, 67, 88 and 31% of patients showed ACR20 responses at 12 weeks. ACR50 responses at 12 weeks were seen in 33, 46, 50, 54 and 8% or patients in the 1, 2, 4 and 8 mg and placebo arms, respectively. Incidence of adverse events was 53% in the placebo arm and 55% in the combined treatment arms, respectively and most adverse events were mild, with no opportunistic infections or deaths reported [&lt;ulink linkID="1494108" linkType="Reference"&gt;1494108&lt;/ulink&gt;]. In June 2014, similar  data were presented at EULAR 2014 Annual Meeting at Paris, France.    A total of 77% of the combined 4- and 8-mg groups achieved ACR20 responses compared with 31% of placebo-treated patients at Week 12. A dose-dependent significant difference was observed versus placebo in the proportion of patients achieving ACR50. Dose-related increases in serum creatinine and both HDL- and LDL-cholesterol were observed at 12 weeks, with the largest changes observed for the 8-mg group. Dose-dependent changes in several bone metabolic markers were reported [&lt;ulink linkID="1565254" linkType="Reference"&gt;1565254&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2008, Incyte reported that a phase IIb trial in rheumatoid arthritis patients was planned for the first half of 2009 [&lt;ulink linkID="959890" linkType="Reference"&gt;959890&lt;/ulink&gt;]. In December 2009, Eli Lilly planned to initiate a phase IIb trial in the second half of 2010 [&lt;ulink linkID="1065190" linkType="Reference"&gt;1065190&lt;/ulink&gt;]. In February 2010, Incyte announced that it would decide whether to participate in the phase IIb program based on the results of the phase II study [&lt;ulink linkID="1075986" linkType="Reference"&gt;1075986&lt;/ulink&gt;]. In October 2010, the global, dose-ranging study (&lt;ulink linkID="69614" linkType="Protocol"&gt;NCT01185353&lt;/ulink&gt;; 13854; I4V-MC-JADA) of an expected 270 patients was initiated and was open for enrollment. The trial was being conducted by Eli Lilly, with Incyte as a collaborator [&lt;ulink linkID="1140913" linkType="Reference"&gt;1140913&lt;/ulink&gt;], [&lt;ulink linkID="1249787" linkType="Reference"&gt;1249787&lt;/ulink&gt;]. In April 2012, the 6 month trial was completed  [&lt;ulink linkID="1284380" linkType="Reference"&gt;1284380&lt;/ulink&gt;]. In June 2012, 12-week results were presented at EULAR 2012 in Berlin, Germany. The primary endpoint, an ACR20 response by 12 weeks in combined 4- and 8-mg dose groups, was 76%, compared with 41% for placebo. The drug was well tolerated [&lt;ulink linkID="1299826" linkType="Reference"&gt;1299826&lt;/ulink&gt;]. In November 2012, data from the trial were to be presented at the 2012 American College of Rheumatology (ACR) annual scientific meeting, in Washington, DC [&lt;ulink linkID="1336757" linkType="Reference"&gt;1336757&lt;/ulink&gt;]. Later that month, 24-week data presented at the same conference showed that in the  2, 4 and 8 mg groups, ACR20 was achieved by   63, 78 and 73% of patients, respectively, ACR50 responses by 20, 48 and 55% s, respectively and ACR70 responses by 10, 28 and 24%, respectively. Results from a magnetic resonance imaging sub-study showed significant improvements in total inflammation score and total joint damage score in the 4 and 8 mg groups compared with placebo at week 12 [&lt;ulink linkID="1340343" linkType="Reference"&gt;1340343&lt;/ulink&gt;]; [&lt;ulink linkID="1343333" linkType="Reference"&gt;1343333&lt;/ulink&gt;]; and decreases in the mean synovitis, osteitis and total inflammation scores were found to be significant at week 12 in the 4 and 8 mg baricitinib groups, when compared with placebo, and these improvements persisted up to week 24 [&lt;ulink linkID="1343335" linkType="Reference"&gt;1343335&lt;/ulink&gt;]. In the same month, further data were presented from 301 patients at the same conference showing that in the baricitinib group, clinically meaningful improvements in most of the patient-reported outcomes were reported as early as week 2 when compare with placebo, and continued until week 12 and 24 [&lt;ulink linkID="1342401" linkType="Reference"&gt;1342401&lt;/ulink&gt;]. In June 2013, data from the long-term extension phase of the study were presented at the EULAR annual congress in Madrid, Spain. At 52 weeks, 71, 49 and 27% of patients achieved ACR20, ACR50 and ACR70, respectively  [&lt;ulink linkID="1438380" linkType="Reference"&gt;1438380&lt;/ulink&gt;] [&lt;ulink linkID="1441897" linkType="Reference"&gt;1441897&lt;/ulink&gt;];  further data were presented at the same conference.Treatment with baricitinib resulted in a dose- and time-dependent increase in the levels of LDL, HDL, triglycerides and total cholesterol from baseline to week 12 through week 24 [&lt;ulink linkID="1441958" linkType="Reference"&gt;1441958&lt;/ulink&gt;]. Similar early response data, showing that a lack or early response was a predictor or a low chance or long-term response were presented in October 2013 at the 77th ACR/ARHP Annual Meeting in San Diego CA [&lt;ulink linkID="1493967" linkType="Reference"&gt;1493967&lt;/ulink&gt;]. In November 2014, further data were presented from the 78th ACR Annual Meeting in Boston, MA. Dose- and time-dependent changes in serum lipids were observed by week 2 after treatment with baricitinib and the changes persisted through 128 weeks. In baricitinib (4 and 8 mg  groups), increases in the apolipoprotein A-1 and apoplipoprotein B were observed at week 4, while no increases were seen in the placebo group [&lt;ulink linkID="1607966" linkType="Reference"&gt;1607966&lt;/ulink&gt;]. The levels of hemoglobin were seen to be highly stable through 64 weeks, whereas lymphocyte counts were decreased [&lt;ulink linkID="1608650" linkType="Reference"&gt;1608650&lt;/ulink&gt;]. In November 2014, further data were presented at the same conference. American college of rheumatology 20, 50 and 70 responses were achieved by 387, 243 and 127 patients, respectively. CDAI remission &amp;lt;/= 2.8 was achieved by 103 patients. Disease activity score 28-erythrocyte sedimentation rate &amp;lt; 2.6 and DAS20 C-reactive protein &amp;lt; 2.6 was seen in 116 and 193 patients, respectively [&lt;ulink linkID="1608760" linkType="Reference"&gt;1608760&lt;/ulink&gt;]. In June 2015, further data were presented at the 16th EULAR Annual European Congress in Rome, Italy. At week 12, MBDA scores were 38.5, 40.8, 36.8, 38.8 and 46.9 in the baricitinib 1, 2, 4 and 8 mg and placebo groups, respectively [&lt;ulink linkID="1670267" linkType="Reference"&gt;1670267&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. At week 12, mean Multi-biomarker disease activity (MBDA) score was 46.9, 36.5, 40.8, 36.8 and 38.8 in placebo, 1, 2, 4 and 8 mg baricitinib groups, respectively. MBDA score of all dose groups of baricitinib was highly correlated with high-sensitivity C-reactive protein (CRP). A weaker correlation was observed between non-CRP based disease activity measures and MBDA scores [&lt;ulink linkID="1767886" linkType="Reference"&gt;1767886&lt;/ulink&gt;]. In November 2017, further data were presented at the 81st ACR Annual Meeting in San Diego, CA. In JADA study of placebo and baricitinib (1, 2, 4 and 8 mg) groups, the mean percentage change in GlycA levels from baseline to week-12 was 495.9, 449.5, 440.7, 441.3 and 434.8 microM, respectively. In JADA study of baricitinib 2, 4 and 8 mg groups, the mean percentage change in GlycA levels from baseline to week-24 was 456.3, 442.8 and 425.2 microM, respectively [&lt;ulink linkID="1978202" linkType="Reference"&gt;1978202&lt;/ulink&gt;] .&lt;/para&gt;&lt;para&gt;In May 2009, Incyte planned to begin a 6-month, double-blind, placebo-controlled, dose-ranging trial in 100 rheumatoid arthritis patients unresponsive to existing therapies, in the US and Europe  [&lt;ulink linkID="1007255" linkType="Reference"&gt;1007255&lt;/ulink&gt;]. By July 2009, this trial (&lt;ulink linkID="55252" linkType="Protocol"&gt;NCT00902486&lt;/ulink&gt;; INCB 28050-201) was underway. The primary endpoints were safety, tolerability and efficacy as measured by ACR20 response rate at 3 months. Secondary endpoints were 6-month safety, tolerability and ACR20, 50, 70 and 90 response measures. The study was scheduled to complete in August 2010 [&lt;ulink linkID="1029977" linkType="Reference"&gt;1029977&lt;/ulink&gt;], [&lt;ulink linkID="1029681" linkType="Reference"&gt;1029681&lt;/ulink&gt;]. In February 2010, the enrollment of 127 patients was completed  [&lt;ulink linkID="1075986" linkType="Reference"&gt;1075986&lt;/ulink&gt;]. In May 2010, topline results were reported showing that 4, 7 and 10 mg doses of baricitinib qd led to rapid improvement of ACR scores and after 3 months were approximately equally effective. At 12 weeks ACR20, 50 and 70 scores included response rates of up to 60, 36 and 16%, respectively, with baricitinib treatment, compared with 32, 13 and 3%, respectively for the placebo group [&lt;ulink linkID="1096513" linkType="Reference"&gt;1096513&lt;/ulink&gt;]. In November 2010, further results were presented at the 2010 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting in Atlanta, GA. At week 24, ACR20, ACR50 and ACR70 response rates were 67, 33 and 26%, respectively, in the 4 mg group , 67, 37 and 30%, respectively, in the 7 mg dose group, and 72, 44 and 28% respectively, in the 10 mg dose group. At week 24, disease activity scores using C-reactive protein (DAS-CRP) of less than 3.2, corresponding to mild disease, were 48, 53 and 65%, respectively, in the 4, 7 and 10 mg groups, and DAS-CRP scores of less than 2.6, corresponding to remission, were 30, 40 and 48%, respectively in the 4, 7 and 10 mg groups [&lt;ulink linkID="1147208" linkType="Reference"&gt;1147208&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Atopic dermatitis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In May 2018, a parallel-assignment, randomized, double-blind, phase III trial (&lt;ulink linkID="329056" linkType="Protocol"&gt;NCT03428100&lt;/ulink&gt;; 16841; I4V-MC-JAIN; 2017-004574-34;  BREEZE-AD4) was initiated in Europe, Brazil, and Japan in adults (n = 500) with moderate to severe atopic dermatitis who have experienced failure to cyclosporine or are intolerant to, or have contraindication to cyclosporine. The primary endpoint was  proportion of participants achieving an IGA score of 0 or 1 with a &amp;gt;/= 2 point improvement. At that time, the trial was expected to complete in March 2021 [&lt;ulink linkID="2116901" linkType="Reference"&gt;2116901&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In March 2018, an interventional, multicenter, randomized, double-blind, phase III trial (&lt;ulink linkID="318565" linkType="Protocol"&gt;NCT03334435&lt;/ulink&gt;; 16587; I4V-MC-JAHN; 2017-000873-35; BREEZE-AD3) was initiated in Argentina, Australia, Europe, India, Israel,  Japan, South Korea, Mexico, Swaziland and Taiwan in adult patients (expected n = 1170) with atopic dermatitis to evaluate the long-term safety and efficacy. The primary end point was to assess the proportion of participants achieving an Investigator's Global Assessment (IGA) score of 0 or 1, for the time frame of 16, 36 and 52 weeks. At that time, the trial was expected to complete in January 2021 [&lt;ulink linkID="2033894" linkType="Reference"&gt;2033894&lt;/ulink&gt;]. In February 2019, topline data were expected later that year [&lt;ulink linkID="2116318" linkType="Reference"&gt;2116318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2018, an interventional, multicenter, randomized, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="329353" linkType="Protocol"&gt;NCT03435081&lt;/ulink&gt;; 17049; I4V-MC-JAIW; BREEZE-AD5) of baricitinib monotherapy was initiated in the US, Canada and Puerto Rico in adult patients (expected n = 450) with moderate to severe atopic dermatitis to evaluate the safety and efficacy. The primary end point was to assess the proportion of participants achieving IGA of 0 or 1 with a ≥ 2 point improvement, for the time frame of 16 weeks. At that time, the trial was expected to complete in August 2020 [&lt;ulink linkID="2033901" linkType="Reference"&gt;2033901&lt;/ulink&gt;]. In February 2019, topline data were expected later that year [&lt;ulink linkID="2116318" linkType="Reference"&gt;2116318&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2017, an interventional, multicenter, randomized, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="318502" linkType="Protocol"&gt;NCT03334422&lt;/ulink&gt;; 16581; I4V-MC-JAHM; 2017-000871-10; BREEZE-AD2) of baricitinib monotherapy was initiated in Argentina, Australia, 	Europe, Israel, Japan, and South Korea in adult patients (expected n = 600) with moderate to severe atopic dermatitis to evaluate the safety and efficacy. The primary end point was to assess the proportion of participants achieving IGA of 0 or 1 with a ≥ 2 point improvement, for the time frame of 16 weeks. At that time, the trial was expected to complete in November 2018 [&lt;ulink linkID="2033900" linkType="Reference"&gt;2033900&lt;/ulink&gt;]. In December 2018, data from the phase III program in severe AD were expected for 1H19 [&lt;ulink linkID="2103847" linkType="Reference"&gt;2103847&lt;/ulink&gt;]. In February 2019, results from the BREEZE-AD2 study were reported showing that the primary endpoint was met; at week 16, a significant proportion of patients treated with baricitinib achieved an IGA score of clear or almost clear.&lt;/para&gt;&lt;para&gt;In October 2017, phase III initiation was planned for AD [&lt;ulink linkID="1975231" linkType="Reference"&gt;1975231&lt;/ulink&gt;]. In November 2017, the interventional, multicenter, randomized, double-blind, parallel-assigned, placebo-controlled, phase III trial (&lt;ulink linkID="318548" linkType="Protocol"&gt;NCT03334396&lt;/ulink&gt;; 16580; I4V-MC-JAHL; 2017-000870-12; BREEZE-AD1) of baricitinib monotherapy was initiated in the US, Europe, India, Japan, Mexico and Taiwan in adult patients (expected n = 600) with moderate to severe atopic dermatitis to evaluate the safety and efficacy. The primary end point was to assess the proportion of participants achieving IGA of 0 or 1 with a ≥ 2 point improvement, for the time frame of 16 weeks. At that time, the trial was expected to complete in January 2019 [&lt;ulink linkID="2033898" linkType="Reference"&gt;2033898&lt;/ulink&gt;]. In February 2019, results from the BREEZE-AD1 study were reported showing that the primary endpoint was met; at week 16, a significant proportion of patients treated with baricitinib achieved an IGA score of clear or almost clear [&lt;ulink linkID="2116318" linkType="Reference"&gt;2116318&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2015, a randomized, double-blind, placebo-controlled, parallel assigned, safety/efficacy, phase II study (&lt;ulink linkID="243327" linkType="Protocol"&gt;NCT02576938&lt;/ulink&gt;; 16284, I4V-MC-JAHG) was planned to be initiated in January 2016, in the US and Japan, in patients (expected n = 120) with moderate-to-severe atopic dermatitis. In February 2016, the trial was initiated, and completed   in March 2017 [&lt;ulink linkID="1707497" linkType="Reference"&gt;1707497&lt;/ulink&gt;]. In September 2017, topline data were presented at the  26th European Academy of Dermatology annual congress in Geneva, Switzerland. The study showed that the drug significantly improved clinical and patient-reported outcomes compared to placebo. At 16 weeks, 61% of the patients treated with the highest dose of baricitinib and a topical corticosteroid achieved at least a 50% reduction in symptoms, compared with 37% for steroid only patients. There was no significant difference at the lower dose of baricitinib between the groups [&lt;ulink linkID="1962535" linkType="Reference"&gt;1962535&lt;/ulink&gt;]. Further clinical data were presented at the same conference. EASI scores were found to be improved statistically compared with placebo as early as week 1 for baricitinib 4 mg (- 27 versus - 11) and week 4 for baricitinib 2 mg (- 58 versus - 16) and were maintained at week 16 (- 60 and – 62, respectively, versus - 27). Patients experienced treatment-emergent adverse events (TEAEs) in placebo, baricitinib 2 mg and 4 mg were 49, 46 and 71%, respectively. AEs at 10, 3 and 13% or lack of efficacy at 18, 11 and 0% of placebo, baricitinib 2 mg and 4 mg, respectively, were the reasons for patients discontinuing from study drug [&lt;ulink linkID="2014661" linkType="Reference"&gt;2014661&lt;/ulink&gt;]. In February 2018, further results of patient-reported Outcomes were presented at the 76th AAD Annual Meeting in San Diego, CA. Starting at week 1, both baricitinib treatment groups demonstrated statistically significant improvements in mean Patient-Oriented Eczema Measure (POEM) scores when compared to placebo; while at week 16, only 4 mg baricitinib treatment group demonstrated significant results with values of -7.5 (p = 0.001), -6.4 (p = 0.007) and -3.5 in 4, 2 mg baricitinib and placebo groups, respectively. At week 1, patients achieved significant improvements in SCOring Atopic Dermatitis (SCORAD) Pruritus; while at week 4, there were significant improvements in SCORAD-sleep and Dermatology Life Quality Index (DLQI) [&lt;ulink linkID="2006681" linkType="Reference"&gt;2006681&lt;/ulink&gt;]. In September 2018, further clinical data were presented from 27th Annual EADV Congress in Paris, France. At week-1, the least square mean changes in efficacy in placebo, baricitinib-2 and 4 mg groups was – 10.7, - 21.8 and – 26.9 (eczema area and severity index (EASI) total score), - 10.7, - 27.6 and – 21.6 (itch numeric rating scale (NRS)), - 14.8, - 30.7 and – 40.2 (sleep disturbance NRS); - 32.3, - 38.4 and – 36.2 (Dermatology Life Quality index (DLQI) total score); - 10.6, - 28.3 and – 33.1 (patient oriented eczema measure), respectively, whereas that observed at week-4 was – 14.9, - 56.9 and – 54.2 (eczema area and severity index (EASI) total score), - 8.7, - 41.3 and – 47.2 (itch numeric rating scale (NRS)), - 26.8, - 43.3 and – 62.9 (sleep disturbance NRS); - 31.2, - 55.9 and – 59.3 (Dermatology Life Quality index (DLQI) total score); - 12.4, - 40.7 and – 52.4 (patient oriented eczema measure), respectively [&lt;ulink linkID="2121987" linkType="Reference"&gt;2121987&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Systemic lupus erythematosus&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In  August 2018, a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (&lt;ulink linkID="348743" linkType="Protocol"&gt;NCT03616912&lt;/ulink&gt;;  16676; I4V-MC-JAHZ; 2017-005026-37; BRAVE I; CTR20190368) of baricitinib began in patients (expected n = 750) in the US, Australia, Europe, Brazil, China, Mexico and Taiwan with SLE. The primary endpoint was percentage of participants achieving a systemic lupus erythematosus responder Index 4 (SRI-4) response (high dose). The study was to complete in February 2021 [&lt;ulink linkID="2104302" linkType="Reference"&gt;2104302&lt;/ulink&gt;], [&lt;ulink linkID="2138774" linkType="Reference"&gt;2138774&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2018, a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (&lt;ulink linkID="349120" linkType="Protocol"&gt;NCT03616964&lt;/ulink&gt;; 16677; I4V-MC-JAIA; 2017-005027-25; BRAVE II) of baricitinib began in patients (expected n = 750) in the US, South America, Europe, India, Japan, South Korea, Philippines, South Africa with SLE. The primary endpoint was percentage of participants achieving a systemic lupus erythematosus responder Index 4 (SRI-4) response (high dose). The study was to complete in February 2021 [&lt;ulink linkID="2104303" linkType="Reference"&gt;2104303&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2016, a randomized, double-blind, placebo-controlled, parallel-group, phase II trial (&lt;ulink linkID="255874" linkType="Protocol"&gt;NCT02708095&lt;/ulink&gt;;  EUDRACT 2015-004404-35) was initiated in patients with SLE (expected n = 300) in the US, Europe, Argentina, South Korea, Mexico and Puerto Rico. The primary endpoint was proportion of participants who achieve remission of arthritis and/or rash defined by the SLE Disease Activity Index 2000 (SLEDAI-2K) [&lt;ulink linkID="1745107" linkType="Reference"&gt;1745107&lt;/ulink&gt;]. In April 2016, the trial was initiated in Taiwan [&lt;ulink linkID="1749339" linkType="Reference"&gt;1749339&lt;/ulink&gt;]. By August 2016, the trial had also been initiated in Japan [&lt;ulink linkID="1745107" linkType="Reference"&gt;1745107&lt;/ulink&gt;].  In November 2017, the trial was completed  [&lt;ulink linkID="1745107" linkType="Reference"&gt;1745107&lt;/ulink&gt;]. In January 2018, the company stated  that the trial completed in December 2017 and data were expected in 2018 [&lt;ulink linkID="2001660" linkType="Reference"&gt;2001660&lt;/ulink&gt;]. In June 2018, phase II data were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands [&lt;ulink linkID="2058547" linkType="Reference"&gt;2058547&lt;/ulink&gt;]. In July 2018, topline data were reported and published from 314 patients. At week 24, resolution of SLEDAI-2K arthritis or rash was achieved by 67.3 and 58% of  patients who received baricitinib 4 or 2 mg, respectively, versus 53.3% of the patients in the placebo group [&lt;ulink linkID="2055945" linkType="Reference"&gt;2055945&lt;/ulink&gt;], [&lt;ulink linkID="2055488" linkType="Reference"&gt;2055488&lt;/ulink&gt;]. In October 2018, further data of type l IFN gene signature were presented at the 82nd ACR Annual Meeting in Chicago, IL. By 24 weeks, baricitinib (2 and 4 mg) versus placebo significantly (p &amp;lt;/= 0.05) reduced the elevated IFN signature observed in 70% of patients at baseline by -20 and -24%, respectively, with decreases observed as early as week-2. Baricitinib 4 mg treatment led to significant clinical improvement in the resolution of arthritis or rash (as assessed by SLEDAI-2K) [&lt;ulink linkID="2084396" linkType="Reference"&gt;2084396&lt;/ulink&gt;]. Further data were presented at the same conference. At week 24, in baricitinib 2 and 4 mg versus placebo groups, SLE Responder Index (SRI)-4 response was achieved by 51.4 and 64.4 versus 47.6% (p &amp;lt;/=0.05), respectively; no worsening (&amp;gt;/=1A/2B) by British Isles Lupus Assessment Group was observed in 78.1 and 81.7 versus 76.2% of patients, respectively; no worsening by Physicians Global Assessment (PGA) of Disease activity was observed in 78.1 and 80.8 versus 74.3% of patients, respectively. Overall, baricitinib treatment was found to be safe and well-tolerated [&lt;ulink linkID="2084414" linkType="Reference"&gt;2084414&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Juvenile idiopathic arthritis&lt;/subtitle&gt;In December 2018, a randomized, double-blind, placebo-controlled, withdrawal, safety and efficacy, phase III trial (&lt;ulink linkID="363229" linkType="Protocol"&gt;NCT03773978&lt;/ulink&gt;; 16276 I4V-MC-JAHV; EUDRACT 2017-004518-24; JUVE-BASIS) was initiated in subjects (expected n = 197) with JIA from 2 years to less than 18 years old in Europe, Japan, China, South America, Israel and Australia. The primary endpoint was time to disease flare. In March 2019, trial completion was expected in August 2021 [&lt;ulink linkID="2128708" linkType="Reference"&gt;2128708&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2018, a clinical trial application for an oral suspension formulation was filed in China [&lt;ulink linkID="2100481" linkType="Reference"&gt;2100481&lt;/ulink&gt;]. By April 2019, an implied clinical trial approval was obtained for  juvenile idiopathic arthritis (JIA) [&lt;ulink linkID="2142223" linkType="Reference"&gt;2142223&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriatic arthritis&lt;/subtitle&gt;In February 2018, a phase III program in PsA was expected to be initiated in 2018 [&lt;ulink linkID="2005757" linkType="Reference"&gt;2005757&lt;/ulink&gt;]. In February 2019, the phase III program in patients with PsA was planned [&lt;ulink linkID="2120023" linkType="Reference"&gt;2120023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriasis&lt;/subtitle&gt;In December 2011, a randomized, double-blind, placebo-controlled, dose-ranging, phase IIb trial (&lt;ulink linkID="83219" linkType="Protocol"&gt;NCT01490632&lt;/ulink&gt;; 14455; I4V-MC-JADP) of oral baricitinib was  initiated  by Eli Lilly and Incyte in the US, Canada and Puerto Rico, in patients (expected n = 240) with moderate to severe chronic plaque psoriasis. At that time, completion was expected in April 2014  [&lt;ulink linkID="1249789" linkType="Reference"&gt;1249789&lt;/ulink&gt;]; in April 2012, primary endpoint results of the trial were expected in 2013  [&lt;ulink linkID="1284380" linkType="Reference"&gt;1284380&lt;/ulink&gt;]. By June 2012, the trial was also recruiting patients in Japan   [&lt;ulink linkID="1249789" linkType="Reference"&gt;1249789&lt;/ulink&gt;], [&lt;ulink linkID="1308103" linkType="Reference"&gt;1308103&lt;/ulink&gt;]. In March 2014, data were presented at the 72nd AAD Annual Meeting in Denver, CO. At week 12, a significantly greater proportion of patients achieved PASI75 in the 8- and 10- mg baricitinib groups compared with placebo (43 and 54%, respectively, versus 15%). Response to treatment was maintained to week 24, with patients initially showing no or only partial response gaining additional benefit through week 16. There were no significant differences in the incidence of treatment-emergent adverse events between baricitinib and placebo, with a low frequency of serious adverse events also reported [&lt;ulink linkID="1537089" linkType="Reference"&gt;1537089&lt;/ulink&gt;], [&lt;ulink linkID="1538107" linkType="Reference"&gt;1538107&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Diabetic kidney disease&lt;/subtitle&gt;In August 2012, a randomized, double-blind, placebo-controlled, phase II study (&lt;ulink linkID="91181" linkType="Protocol"&gt;NCT01683409&lt;/ulink&gt;; 14734; I4V-MC-JAGQ) began in the US in patients (expected n = 250) with diabetic kidney disease. By February 2013, sites were also recruiting patients in Japan and Puerto Rico. At that time, the study was expected to complete in January 2014 [&lt;ulink linkID="1326195" linkType="Reference"&gt;1326195&lt;/ulink&gt;]. In June 2015, clinical data were presented from 129 patients at the 75th ADA Scientific Sessions in Boston, MA. Baricitinib statistically significantly reduced the primary efficacy measure of UACR change from baseline to 6 months in a dose-dependent manner. Unexpected safety signals were not found and anemia was more frequently reported in the highest dose group when compared with the placebo group [&lt;ulink linkID="1668069" linkType="Reference"&gt;1668069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Alopecia areata&lt;/subtitle&gt;In June 2018, a randomized, parallel-assignment, double-blind, placebo-controlled, multi-center, operationally seamless, adaptive phase II/III study (&lt;ulink linkID="344483" linkType="Protocol"&gt;NCT03570749&lt;/ulink&gt;; 16582; I4V-MC-JAHO; BRAVE-AA1) was to be initiated in September 2018, to assess the safety and efficacy of Baricitinib (oral) versus placebo in patients (expected n = 725) with severe or very severe alopecia areata. The primary endpoint was percentage of participants treated with the high dose baricitinib achieving Alopecia Areata Investigator's Global Assessment (AA-IGA) 0 or 1 with a ≥2 point improvement.  In September 2018, the trial was 	initiated in the US,  Puerto Rico, Japan, Mexico,  and South Korea. At that time, the trial was expected to complete in August 2022 [&lt;ulink linkID="2050597" linkType="Reference"&gt;2050597&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Primary biliary cholangitis&lt;/subtitle&gt;In November 2018, an randomized, parallel assignment, double-blind, placebo-controlled, proof-of-concept , phase II trial (&lt;ulink linkID="360237" linkType="Protocol"&gt;NCT03742973&lt;/ulink&gt;; 17039; I4V-MC-JAIV) to evaluate the safety and efficacy of baricitinib  in subjects (expected n = 52) with primary biliary cholangitis who have an inadequate response or are intolerant to &lt;ulink linkID="13338" linkType="Drug"&gt;ursodeoxycholic acid&lt;/ulink&gt; was planned to be initiated in December 2018 in the US and Puerto Rico. At that time, the trial was expected to complete in October 2020 [&lt;ulink linkID="2096972" linkType="Reference"&gt;2096972&lt;/ulink&gt;]. In March 2019, the study was initiated  [&lt;ulink linkID="2096972" linkType="Reference"&gt;2096972&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In October 2018, clinical data were presented 82nd ACR Annual Meeting in Chicago, IL. Individual patient data from the baricitinib (4 mg) arm from RA-BEGIN were weighted to match baseline characteristics of the adalimumab arm from PREMIER, tofacitinib (5 mg) arm from ORAL-START, and tocilizumab (8 mg/kg) arm from each or combination of AMBITION and FUNCTION, respectively; methotrexate arms were also matched between trials using matching-adjusted indirect comparisons. Compared with adalimumab and tocilizumab, statistically significant improvement in pain was observed with baricitinib treated group with all three matching methods but only with the Bucher method for tofacitinib [&lt;ulink linkID="2084121" linkType="Reference"&gt;2084121&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2018, data from dataset studies were presented to evaluate the long-term safety of baricitinib in 3,492 patients with RA at the 82nd ACR Annual Meeting in Chicago, IL. Patients who had been previously exposed to any baricitinib dose from eight randomized trials (four phase III, three phase II, one phase Ib) and one ongoing long-term extension study (data up to 01-April-2017) were randomized to receive 2 or 4 mg baricitinib for 7860 total PY of exposure.IR of adverse events did not increase with prolonged exposure. Malignancy (excluding non-melanoma skin cancer) IR were 0.5 and 1.2 for 2mg and mg, respectively, with as-treated analysis and 0.8 and 0.8 with as-randomized analysis. The following IRs was observed in the current all- baricitinib -RA: gastrointestinal perforation (0.04), and tuberculosis (0.14). Less than 1% of patients discontinued due to abnormal lab results [&lt;ulink linkID="2084152" linkType="Reference"&gt;2084152&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2018, clinical data from randomized, methotrexate-controlled studies which compared improvement in pain and HAQ-DI with baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapy in csDMARD rheumatoid arthritis patients using matching-adjusted indirect comparisons were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. Individual patient data from the RA-BEGIN baricitinib 4 mg arm were weighted to match baseline characteristics of the adalimumab arm (PREMIER), tofacitinib 5 mg arm (ORAL-START) and tocilizumab 8 mg/kg arm (from each or combination of AMBITION and FUNCTION, respectively);  methotrexate arms were also matched between trials. Baricitinib showed statistically significant improvement in pain compared with adalimumab and tocilizumab with all three matching methods but only with the Bucher method for tofacitinib. Significant improvements in Health Assessment Questionnaire-Disability Index scores were observed with baricitinib compared with adalimumab and tocilizumab but not tofacitinib  [&lt;ulink linkID="2045167" linkType="Reference"&gt;2045167&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, clinical data from a study (NCT01724580) were presented at the 81st ACR Annual Meeting in San Diego, CA. Patients (n = 18) received baricitinib (between 0.1 to 17 mg, qd) for up to 53 months. IFN-alpha stimulated STAT-1 phosphorylation (pSTAT-1) in immune cells from Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature (CANDLE) and STING Associated Vasculopathy with onset during Infancy patients negatively correlated with plasma baricitinib levels. With increased drug exposure, 25-gene IFN score and serum IP-10 levels, both markers of IFN signaling were significantly decreased. A subset of CANDLE patients normalized the 25-gene IFN score at AUC24,ss values between 1500 to 2000 nM*h, but higher exposures were required in patients with more severe disease [&lt;ulink linkID="1978193" linkType="Reference"&gt;1978193&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2017, meta-analysis data from published randomized controlled trials (RCT) and corresponding long-term extension studies, which evaluated the efficacy of tofacitinib, and baricitinib in combination with DMARDs, in patients with rheumatoid arthritis were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. In RCTs of baricitinib, for 2 and 4 mg qd treatment, the corresponding incidence rate of serious infection events was 4.75 and 3.57, respectively. The risk differences in RA-BEGIN study for 4 mg qd baricitinib versus methotrexate was -0.04 and -1.48 for monotherapy and combination therapy, respectively [&lt;ulink linkID="1935534" linkType="Reference"&gt;1935534&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I trials&lt;/subtitle&gt;In January 2015, an open label, single group assigned phase I trial was initiated to assess the absolute bioavailability of baricitinib in healthy subjects (n = 8). In February 2015, the trial was completed [&lt;ulink linkID="1635565" linkType="Reference"&gt;1635565&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2009, a multiple-dose phase I trial and a 28-day drug interaction study had been completed. Results showed the drug was well tolerated [&lt;ulink linkID="985021" linkType="Reference"&gt;985021&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2008, clinical trials were planned for  mid-2008 [&lt;ulink linkID="865996" linkType="Reference"&gt;865996&lt;/ulink&gt;], [&lt;ulink linkID="866194" linkType="Reference"&gt;866194&lt;/ulink&gt;]. By July 2008, a single dose-escalation phase I trial had been completed. The drug was well tolerated and showed pharmacokinetic and pharmacodynamic properties suited for a multiple dose-escalation study [&lt;ulink linkID="929349" linkType="Reference"&gt;929349&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2015, clinical data were presented from eight clinical pharmacology studies  in healthy subjects and in rheumatoid arthritis patients at the 16th EULAR Annual European Congress in Rome, Italy.​ In healthy subjects, co-administration of &lt;ulink linkID="44299" linkType="Drug"&gt;ketoconazole&lt;/ulink&gt; or &lt;ulink linkID="44292" linkType="Drug"&gt;fluconazole&lt;/ulink&gt; with baricitinib did not show significant effects on the pharmacokinetics of baricitinib. In patients with rheumatoid arthritis, the combination of methotrexate and baricitinib had no significant effect on the pharmacokinetics of baricitinib or methotrexate. Baricitinib was well tolerated [&lt;ulink linkID="1668757" linkType="Reference"&gt;1668757&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2016, preclinical data were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. IC50 (nm) values in B cells, CD4+ T cells, CD8+ T cells, NK cells, and monocytes ranged from 17 to 246, 21 to 77, 24 to 117, 17 to 137, 13 to 165 (baricitinib); 18 to 61, 9 to 59, 9 to 91, 6 to 61, and 9 to 221 (tofacitinib), respectively. Greater duration of inhibition of cytokine signaling with tofacitinib over baricitinib, but not limited to signaling mediated by IL-15 and IL-21 on NK cells [&lt;ulink linkID="1767417" linkType="Reference"&gt;1767417&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, preclinical data were presented at the 55th Society of Toxicology Annual Meeting in New Orleans, LA. Baricitinib associated dose dependent increase in survival rates was observed in rats and was attributed to the decreased incidence of hematopoietic and mammary neoplasms, likely secondary to test article-related decreased weight gain. Baricitinib in rats was found to be well tolerated. Decrease in the incidence of proliferative changes including incidences of neoplastic and hyperplastic lesions in the mammary glands of females and in the liver of males and females was observed [&lt;ulink linkID="1749623" linkType="Reference"&gt;1749623&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, preclinical data were presented at CHI's inaugural Anti-Inflammatories: Small-Molecule Approaches Meeting in San Diego, CA. INCB-28050 demonstrated efficacy when administered orally in a adjuvant-induced RA model. The compound was efficacious and well tolerated at once-daily doses [&lt;ulink linkID="1099137" linkType="Reference"&gt;1099137&lt;/ulink&gt;]. In June 2011, similar data were presented at the CHI's Ninth Next-Gen Kinase Inhibitors Conference in Cambridge, MA. In the mouse CIA model, bid dosing improved disease severity  at the 3 and 10 mg/kg without much immune suppression measured in the humoral systems. The compound has also shown efficacy in an anticollagen antibody induced model [&lt;ulink linkID="1201009" linkType="Reference"&gt;1201009&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2008, preclinical studies were ongoing [&lt;ulink linkID="865996" linkType="Reference"&gt;865996&lt;/ulink&gt;], [&lt;ulink linkID="866194" linkType="Reference"&gt;866194&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In February 2013, the EMA's Pediatric Committee adopted a positive opinion on a pediatric investigation plan for baricitinib for the treatment of chronic idiopathic arthritis  [&lt;ulink linkID="1384167" linkType="Reference"&gt;1384167&lt;/ulink&gt;]. In December 2017, the committee agreed modifications to the PIP [&lt;ulink linkID="1998573" linkType="Reference"&gt;1998573&lt;/ulink&gt;]. In May 2018, the EMA's Pediatric Committee adopted a positive opinion on modifications to a PIP for baricitinib for the treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and JIA) [&lt;ulink linkID="2031838" linkType="Reference"&gt;2031838&lt;/ulink&gt;]. In July 2018, the EMA's Pediatric Committee adopted a positive opinion agreeing a pediatric investigation plan for treatment of atopic dermatitis [&lt;ulink linkID="2062871" linkType="Reference"&gt;2062871&lt;/ulink&gt;]. In November 2018, the EMA's Pediatric Committee had discussions on modifications of an agreed PIP for the treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and JIA) [&lt;ulink linkID="2134764" linkType="Reference"&gt;2134764&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-09-01T00:00:00.000Z</StatusDate><Source id="1962811" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-04-05T00:00:00.000Z</StatusDate><Source id="1918432" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-06-30T00:00:00.000Z</StatusDate><Source id="2058547" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-04-05T00:00:00.000Z</StatusDate><Source id="1918432" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-04-25T00:00:00.000Z</StatusDate><Source id="1921007" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-11T00:00:00.000Z</StatusDate><Source id="1999945" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-01-23T00:00:00.000Z</StatusDate><Source id="2008046" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-11-17T00:00:00.000Z</StatusDate><Source id="1994366" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1942703" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-08-17T00:00:00.000Z</StatusDate><Source id="2071617" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1942703" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-07-01T00:00:00.000Z</StatusDate><Source id="2169462" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2564">Alopecia areata</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2050597" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2564">Alopecia areata</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2050597" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2018-12-17T00:00:00.000Z</StatusDate><Source id="2128708" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2018-12-17T00:00:00.000Z</StatusDate><Source id="2128708" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2018-02-20T00:00:00.000Z</StatusDate><Source id="2033901" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-26T00:00:00.000Z</StatusDate><Source id="2033900" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2564">Alopecia areata</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2050597" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2018-12-17T00:00:00.000Z</StatusDate><Source id="2128708" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2564">Alopecia areata</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2050597" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-26T00:00:00.000Z</StatusDate><Source id="2033900" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="SZ">Swaziland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2018-03-16T00:00:00.000Z</StatusDate><Source id="2033894" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-26T00:00:00.000Z</StatusDate><Source id="2033900" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2564">Alopecia areata</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2050597" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2018-12-17T00:00:00.000Z</StatusDate><Source id="2128708" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2013-01-22T00:00:00.000Z</StatusDate><Source id="1386078" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2018-12-17T00:00:00.000Z</StatusDate><Source id="2128708" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-26T00:00:00.000Z</StatusDate><Source id="2033900" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2018-02-20T00:00:00.000Z</StatusDate><Source id="2033901" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2018-12-17T00:00:00.000Z</StatusDate><Source id="2128708" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate>2019-03-28T00:00:00.000Z</StatusDate><Source id="2096972" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate>2019-03-28T00:00:00.000Z</StatusDate><Source id="2096972" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate>2019-03-28T00:00:00.000Z</StatusDate><Source id="2096972" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1745107" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate>2019-03-28T00:00:00.000Z</StatusDate><Source id="2096972" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2017-04-25T00:00:00.000Z</StatusDate><Source id="1921458" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2921">Spondylarthritis</Indication><StatusDate>2017-02-14T00:00:00.000Z</StatusDate><Source id="1900914" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2564">Alopecia areata</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2921">Spondylarthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2564">Alopecia areata</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="SZ">Swaziland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2564">Alopecia areata</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2016-07-19T00:00:00.000Z</StatusDate><Source id="1784057" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2146680" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2009-07-30T00:00:00.000Z</StatusDate><Source id="1029977" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-10-31T00:00:00.000Z</StatusDate><Source id="1249787" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-10-31T00:00:00.000Z</StatusDate><Source id="1249787" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-10-31T00:00:00.000Z</StatusDate><Source id="1249787" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-12-31T00:00:00.000Z</StatusDate><Source id="1256042" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-10-31T00:00:00.000Z</StatusDate><Source id="1249787" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-10-31T00:00:00.000Z</StatusDate><Source id="1249787" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-10-31T00:00:00.000Z</StatusDate><Source id="1249787" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-07-22T00:00:00.000Z</StatusDate><Source id="1580377" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-07-22T00:00:00.000Z</StatusDate><Source id="1580377" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2009-07-30T00:00:00.000Z</StatusDate><Source id="1029977" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2015-10-14T00:00:00.000Z</StatusDate><Source id="1707497" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-03-10T00:00:00.000Z</StatusDate><Source id="1745107" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1745107" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2013-02-08T00:00:00.000Z</StatusDate><Source id="1326195" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2013-02-08T00:00:00.000Z</StatusDate><Source id="1326195" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2013-02-08T00:00:00.000Z</StatusDate><Source id="1326195" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2012-06-18T00:00:00.000Z</StatusDate><Source id="1249789" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2011-12-19T00:00:00.000Z</StatusDate><Source id="1249789" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2011-12-19T00:00:00.000Z</StatusDate><Source id="1249789" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2011-12-19T00:00:00.000Z</StatusDate><Source id="1249789" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2011-12-19T00:00:00.000Z</StatusDate><Source id="1249789" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2011-12-19T00:00:00.000Z</StatusDate><Source id="1249789" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2011-12-19T00:00:00.000Z</StatusDate><Source id="1249789" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2012-08-31T00:00:00.000Z</StatusDate><Source id="1326195" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2012-06-18T00:00:00.000Z</StatusDate><Source id="1249789" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2012-08-31T00:00:00.000Z</StatusDate><Source id="1326195" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2013-02-08T00:00:00.000Z</StatusDate><Source id="1326195" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1745107" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-01-28T00:00:00.000Z</StatusDate><Source id="1730341" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-02-13T00:00:00.000Z</StatusDate><Source id="1899930" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-02-13T00:00:00.000Z</StatusDate><Source id="1899930" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1770977" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1770977" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-07-03T00:00:00.000Z</StatusDate><Source id="1942601" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2016-02-04T00:00:00.000Z</StatusDate><Source id="1707497" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-30T00:00:00.000Z</StatusDate><Source id="1387846" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2016-02-04T00:00:00.000Z</StatusDate><Source id="1707497" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-13T00:00:00.000Z</StatusDate><Source id="1992220" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-01-31T00:00:00.000Z</StatusDate><Source id="2005757" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-06-01T00:00:00.000Z</StatusDate><Source id="2040566" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-12T00:00:00.000Z</StatusDate><Source id="1992220" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-06-01T00:00:00.000Z</StatusDate><Source id="2040566" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2009-12-21T00:00:00.000Z</StatusDate><Source id="1065190" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-30T00:00:00.000Z</StatusDate><Source id="1387846" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1745107" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1745107" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-02-15T00:00:00.000Z</StatusDate><Source id="2005757" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1745107" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-04-01T00:00:00.000Z</StatusDate><Source id="1749339" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1745107" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1745107" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2016-08-30T00:00:00.000Z</StatusDate><Source id="1745107" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1942703" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1942601" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2017-01-13T00:00:00.000Z</StatusDate><Source id="1892460" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-30T00:00:00.000Z</StatusDate><Source id="1387846" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-03-09T00:00:00.000Z</StatusDate><Source id="2085262" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-01-23T00:00:00.000Z</StatusDate><Source id="2008046" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-11T00:00:00.000Z</StatusDate><Source id="1999945" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2013-01-22T00:00:00.000Z</StatusDate><Source id="1386078" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-08-17T00:00:00.000Z</StatusDate><Source id="2071617" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1386085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-30T00:00:00.000Z</StatusDate><Source id="1387846" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-11-17T00:00:00.000Z</StatusDate><Source id="1994366" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2018-02-20T00:00:00.000Z</StatusDate><Source id="2033901" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2018-02-20T00:00:00.000Z</StatusDate><Source id="2033901" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-26T00:00:00.000Z</StatusDate><Source id="2033900" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-26T00:00:00.000Z</StatusDate><Source id="2033900" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-26T00:00:00.000Z</StatusDate><Source id="2033900" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="SZ">Swaziland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2018-03-16T00:00:00.000Z</StatusDate><Source id="2033894" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-23T00:00:00.000Z</StatusDate><Source id="2033898" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-11-26T00:00:00.000Z</StatusDate><Source id="2033900" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104303" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-08-02T00:00:00.000Z</StatusDate><Source id="2104302" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2921">Spondylarthritis</Indication><StatusDate>2017-02-14T00:00:00.000Z</StatusDate><Source id="1900914" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2564">Alopecia areata</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2050597" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2564">Alopecia areata</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2050597" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2564">Alopecia areata</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2050597" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate>2018-11-15T00:00:00.000Z</StatusDate><Source id="2096972" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate>2018-11-15T00:00:00.000Z</StatusDate><Source id="2096972" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-03-09T00:00:00.000Z</StatusDate><Source id="2085262" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2008-01-08T00:00:00.000Z</StatusDate><Source id="865996" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2008-07-29T00:00:00.000Z</StatusDate><Source id="929349" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2008-07-29T00:00:00.000Z</StatusDate><Source id="929349" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="17810">Eli Lilly &amp; Co</OwnerCompany><Country id="US">US</Country><Indication id="318">Systemic lupus erythematosus</Indication><AwardedIndication>Treatment of systemic lupus erythematosus</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-12-13T00:00:00.000Z</MileStoneDate><Source id="2103847" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17810">Eli Lilly &amp; Co</OwnerCompany><Country id="US">US</Country><Indication id="318">Systemic lupus erythematosus</Indication><AwardedIndication>Treatment of pediatric systemic lupus erythematosus</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-11-02T00:00:00.000Z</MileStoneDate><Source id="1981412" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="17810">Eli Lilly &amp; Co</OwnerCompany><Country id="EU">EU</Country><Indication id="1102">Atopic dermatitis</Indication><AwardedIndication>Treatment of atopic dermatitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-07-27T00:00:00.000Z</MileStoneDate><Source id="2062871" type="PR"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="17810">Eli Lilly &amp; Co</OwnerCompany><Country id="CN">China</Country><Indication id="291">Rheumatoid arthritis</Indication><AwardedIndication>Rheumatoid arthritis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-10-17T00:00:00.000Z</MileStoneDate><Source id="2085262" type="OTHER"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01184"><Name>Jak1 tyrosine kinase</Name><SwissprotNumbers><Swissprot>O12990</Swissprot><Swissprot>P23458</Swissprot><Swissprot>P52332</Swissprot><Swissprot>Q09178</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01185"><Name>Jak2 tyrosine kinase</Name><SwissprotNumbers><Swissprot>O60674</Swissprot><Swissprot>Q62120</Swissprot><Swissprot>Q62689</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1075759">Aclaris Therapeutics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1121408">Vixen Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17216">Incyte Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17810">Eli Lilly &amp; Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(cn2)c3c4cc[nH]c4ncn3</Smiles></StructureSmiles><Deals><Deal id="129106" title="Eli Lilly to develop Incyte's INCB-28050 and certain follow on compounds for RA worldwide                       "/><Deal id="159512" title="Aclaris Therapeutics to acquire Vixen Pharmaceuticals   "/></Deals><PatentFamilies><PatentFamily id="1242033" number="WO-2012061537" title="Methods for treating hair loss disorders"/><PatentFamily id="2504731" number="WO-2009114512" title="Azetidine and cyclobutane derivatives as JAK inhibitors."/><PatentFamily id="2599363" number="WO-2013149194" title="Methods for treating hair loss disorders"/><PatentFamily id="2682939" number="WO-2014028756" title="Deuterated baricitinib"/><PatentFamily id="2836345" number="WO-2014194195" title="Cyclodextrin-based polymers for the therapeutic delivery"/><PatentFamily id="3038063" number="WO-2015145286" title="Amorphous form of baricitinib"/><PatentFamily id="3063066" number="WO-2015166434" title="Crystalline form of baricitinib"/><PatentFamily id="3188452" number="CN-105541891" title="An intermediate of baritinib and preparation method and method of preparing baritinib by intermediate"/><PatentFamily id="3202255" number="WO-2016088094" title="Process for the preparation of baricitinib and an intermediate thereof"/><PatentFamily id="3206043" number="CN-105601635" title="Rake bar h crystal of crystal form a and i crystal form of florfenicol phosphate and preparation method thereof"/><PatentFamily id="3270302" number="CN-105566332" title="Palladium trifluoroacetate a crystal form, b crystal form and preparation method thereof"/><PatentFamily id="3277926" number="WO-2016125080" title="Process for the preparation of baricitinib and an intermediate thereof"/><PatentFamily id="3318279" number="WO-2016135286" title="Method for stimulating dendritic cells (DCs)"/><PatentFamily id="3359929" number="WO-2016141891" title="Crystal form of jak inhibitor and preparation method thereof"/><PatentFamily id="3482254" number="WO-2016205487" title="Processes and intermediates for the preparation of {1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile"/><PatentFamily id="3601304" number="CN-106554363" title="A preparation method of baricitinib intermediate"/><PatentFamily id="3701212" number="WO-2017109524" title="Method and intermediate for the production of baricitinib"/><PatentFamily id="3730643" number="CN-106924205" title="Sustained-release preparation containing baricitinib"/><PatentFamily id="3737773" number="WO-2017125772" title="Baricitinib salts"/><PatentFamily id="3741637" number="CN-106946917" title="A new synthetic method of jak inhibitor nylon and intermediates thereof"/><PatentFamily id="3802362" number="CN-107176955" title="A baricitinib preparation method"/><PatentFamily id="3950649" number="WO-2018029641" title="Method of manufacturing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine"/><PatentFamily id="3977017" number="CN-107739328" title="Preparation method for synthesizing key intermediate 1 of baricitinib"/><PatentFamily id="4035788" number="CN-107915738" title="Preparation method of key intermediate 2 for synthesis of baricitinib"/><PatentFamily id="4051889" number="EP-03321267" title="Crystalline forms of 2-[1-ethylsulfonyl-3-[7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile salts and preparation thereof"/><PatentFamily id="4071637" number="WO-2018099680" title="Citrate salts of a janus kinase (jak) inhibitor"/><PatentFamily id="4087331" number="TW-0I616447" title="Crystal form D of baricitinib phosphate and composition thereof"/><PatentFamily id="4090116" number="WO-2019114258" title="Method for preparing baricitinib"/><PatentFamily id="4104353" number="WO-2018113801" title="Crystalline forms of 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile with phosphoric acid and a method of their preparation"/><PatentFamily id="4147952" number="CN-108341818" title="Rake bar of pirfenidone and its phosphate new crystal form and preparation method thereof"/><PatentFamily id="4286611" number="WO-2018217700" title="Glucuronide prodrugs of janus kinase inhibitors"/><PatentFamily id="4315164" number="CN-108976233" title="Impurity of baritinib and preparation and detection method thereof"/><PatentFamily id="4320986" number="WO-2018233437" title="Crystal form of baricitinib and preparation method thereof"/><PatentFamily id="4328674" number="WO-2019003249" title="Polymorphic forms of baricitinib"/><PatentFamily id="4363081" number="WO-2019018394" title="Treating rheumatoid arthritis"/><PatentFamily id="4462063" number="WO-2019071276" title="Methods and compositions for treating urea cycle disorders, in particular OTC deficiency"/><PatentFamily id="4496295" number="WO-2019089962" title="Drug delivery system for treating disease"/><PatentFamily id="4561583" number="WO-2019121290" title="Co-crystal of an orally available janus kinase inhibitor"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>9</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>15</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Portland" id="1004327"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Children's Cancer Research Institute" id="1007412"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Southeast University" id="1008666"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chunghwa Chemical Synthesis &amp; Biotech Co Ltd" id="1009929"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CoNCERT Pharmaceuticals Inc" id="1021896"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dare Bioscience Inc" id="1032593"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Activartis Biotech GmbH" id="1047898"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sino Biopharmaceutical Ltd" id="1073089"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Yoko Pharmaceutical Co Ltd" id="1074506"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aclaris Therapeutics Inc" id="1075759"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Huawe Medicine Technology Development Co Ltd" id="1076471"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Crystal Pharmatech Co Ltd" id="1077753"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xiamen Henry BioChem Co Ltd" id="1079413"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Theravance Biopharma Inc" id="1096800"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Xuanchuang Biological Technology Co Ltd" id="1105209"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Zhongbang Pharmaceutical Co Ltd" id="1111446"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hangzhou Cheminspire technologies Co Ltd" id="1114702"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vixen Pharmaceuticals Inc" id="1121408"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advent International" id="1123769"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Siegfried (Nantong) Pharmaceuticals Co Ltd" id="1160549"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Camp4 Therapeutics Corp" id="1174775"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xiamen Halosyntech Co., Ltd" id="1175443"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Osteoanalgesia LLC" id="1186061"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Incyte Corp" id="17216"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Servier" id="19863"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Columbia University" id="20559"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></drugRecordsOutput>